

# CITATION REPORT

List of articles citing

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients

DOI: 10.1016/0002-9343(80)90380-0

American Journal of Medicine, 1980, 69, 204-17.

**Source:** <https://exaly.com/paper-pdf/14881814/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2225	Systemic Disease and the Liver. 897-927		1
2224	Early bone marrow transplantation in acute leukemia. <b>1980</b> , 41, 405-10		2
2223	An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. <b>1980</b> , 79, 1178-1191		235
2222	Oral and ophthalmic pathology of graft versus host disease in man: predictive value of the lip biopsy. <b>1981</b> , 12, 1022-30		106
2221	Graft versus host disease. <b>1981</b> , 5, 595-9		18
2220	TRANSPLANTATION OF STEM CELLS FROM FETAL LIVER. <b>1981</b> , 317, 1193-1194		
2219	The How of Breast Milk and Infection. <b>1981</b> , 317, 1192-1193		
2218	Esophageal abnormalities in chronic graft-versus-host disease in humans. <b>1981</b> , 80, 914-921		121
2217	Aplastic anemia: biology and treatment. <b>1981</b> , 95, 477-94		58
2216	Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. <b>1981</b> , 304, 1529-33		899
2215	Deficiency of intestinal immunity with graft-vs.-host disease in humans. <b>1981</b> , 144, 38-46		43
2214	Fatal airway disease in an adult with chronic graft-versus-host disease. <b>1982</b> , 37, 77-8		76
2213	Allosuppressor and allohelper T cells in acute and chronic graft-vs-host disease. I. Alloreactive suppressor cells rather than killer T cells appear to be the decisive effector cells in lethal graft-vs.-host disease. <b>1982</b> , 155, 1501-22		64
2212	Dental management of the child undergoing bone marrow transplantation. <b>1982</b> , 104, 485-8		4
2211	Primary biliary cirrhosis and liver transplantation. <b>1982</b> , 306, 41-3		23
2210	Opportunistic infections and Kaposi's sarcoma in homosexual men. <b>1982</b> , 306, 932-5		3
2209	Recurrence of primary biliary cirrhosis after liver transplantation. <b>1982</b> , 306, 1-4		231

2208	Sequential morphology of graft-versus-host disease in the rat radiation chimera. <b>1982</b> , 22, 203-24	51
2207	Hemolytic uremic syndrome after bone marrow transplantation. <b>1982</b> , 67, 206-10	23
2206	Bone marrow transplantation in children. <b>1982</b> , 49, 317-24	
2205	[Bone marrow transplantation in patients with leukemia]. <b>1982</b> , 60, 1279-87	13
2204	The pathology of head and neck tumors: the lymphoepithelial lesion and Sjögren's syndrome, Part 16. <b>1982</b> , 5, 150-63	23
2203	The occurrence of cancer in immune deficiencies. <b>1982</b> , 6, 1-64	51
2202	Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren's syndrome). <b>1982</b> , 395, 11-43	171
2201	Melanocyte-lymphocyte interaction in human graft-versus-host disease. <b>1983</b> , 10, 305-11	10
2200	Allogeneic bone-marrow transplantation. <b>1983</b> , 71, 77-102	110
2199	Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. <b>1983</b> , 77, 1-12	162
2198	B-cell hyperactivity in murine lupus II. Defects in response to and production of accessory signals in lupus-prone mice. <b>1983</b> , 4, 317-9	24
2197	The graft-versus-host reaction. <b>1983</b> , 14, 3-5	22
2196	The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients. <b>1983</b> , 14, 29-35	21
2195	Ocular manifestations of graft-vs-host disease. <b>1983</b> , 90, 4-13	159
2194	The acute abdomen in the immunologically compromised child. <b>1983</b> , 18, 937-44	38
2193	Graft-vs.-host-associated immune suppression is activated by recognition of allogeneic murine I-A antigens. <b>1983</b> , 157, 936-46	34
2192	Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A. <b>1983</b> , 157, 755-71	108
2191	A cloned major histocompatibility complex-restricted trinitrophenyl-reactive human helper T cell line that activates B cell subsets via two distinct pathways. <b>1983</b> , 158, 1444-58	29

2190	Graft-v-Host Disease. <b>1983</b> , 119, 683	19
2189	Ocular manifestations of graft-v-host disease. <b>1983</b> , 101, 1080-4	86
2188	The eye in bone marrow transplantation. I. Clinical study. <b>1983</b> , 101, 580-4	123
2187	The eye in bone marrow transplantation. II. Histopathology. <b>1983</b> , 101, 585-90	61
2186	Ineffectiveness of haemodialysis in atropine poisoning. <b>1983</b> , 286, 2023-4	1
2185	Idiopathic thrombocytopenic purpura following bone marrow transplantation. <b>1983</b> , 69, 47-51	14
2184	Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine. <b>1983</b> , 5, 313-8	17
2183	Chronic graft versus host disease presenting with polymyositis. <b>1983</b> , 286, 2024	24
2182	Syndrome Resembling Graft-Versus-Host Disease in a Patient with Disseminated Carcinoma1. <b>1983</b> , 76, 703-705	8
2181	Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. <b>1983</b> , 98, 461-6	202
2180	Persistent diffuse lymphadenopathy in homosexual men: endpoint or prodrome?. <b>1984</b> , 100, 801-8	110
2179	Destruction of the intestinal mucosa after bone marrow transplantation and graft-versus-host disease. <b>1984</b> , 3, 264-74	3
2178	Allosuppressor and allohelper T cells in acute and chronic graft-vs-host disease. V. F1 mice with secondary chronic GVHD contain F1-reactive allohelper but no allosuppressor T cells. <b>1984</b> , 159, 508-23	25
2177	Airways obstruction associated with graft versus host disease after bone marrow transplantation. <b>1984</b> , 39, 887-94	64
2176	Gingival lesions in leukemia. A classification. <b>1984</b> , 55, 585-8	33
2175	Graft-versus-host disease: pathophysiological and clinical aspects. <b>1984</b> , 35, 11-24	118
2174	Allogeneic marrow transplantation. <b>1984</b> , 2, 27-38	25
2173	Oral Patterns of Acute and Chronic Graft-v-Host Disease. <b>1984</b> , 120, 1461	37

2172	Oral Manifestations of Chronic Graft-v-Host Disease. <b>1984</b> , 144, 1591	101
2171	Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. <b>1984</b> , 5, 324-32	311
2170	B-cell-tropic interleukins in murine systemic lupus erythematosus (SLE) 1. <b>1984</b> , 78, 159-83	53
2169	Late onset pyridoxine-responsive sideroblastic anaemia after allogeneic bone marrow transplantation. <b>1984</b> , 56, 153-6	6
2168	BONE MARROW TRANSPLANTATION: A REVIEW OF DELAYED COMPLICATIONS. <b>1984</b> , 57, 185-208	133
2167	Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. <b>1984</b> , 4, 123-30	152
2166	Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. <b>1984</b> , 27, 1-12	220
2165	Neurological complications of bone marrow transplantation in childhood. <b>1984</b> , 16, 569-76	93
2164	Marrow transplantation in hepatitis-associated aplastic anemia. <b>1984</b> , 17, 269-78	29
2163	[Bone marrow transplantation in panmyelopathy, acute leukemia and chronic myelocytic leukemia: results of the Ulm Transplantation Group]. <b>1984</b> , 62, 577-85	3
2162	Mononuclear-cell subsets in human idiopathic crescentic glomerulonephritis (ICGN): analysis in tissue sections with monoclonal antibodies. <b>1984</b> , 4, 202-8	32
2161	Cyclosporin for pulmonary sarcoidosis. <b>1984</b> , 1, 1174	33
2160	Spanish toxic oil syndrome is a chemically induced GVHD-like epidemic. <b>1984</b> , 1, 1174-5	25
2159	VISUAL FATIGUE AND VISUALLY EVOKED POTENTIALS IN MULTIPLE SCLEROSIS. <b>1984</b> , 324, 731-732	
2158	Chronic obstructive airways disease after bone marrow transplantation. <b>1984</b> , 105, 370-6	39
2157	Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. <b>1984</b> , 15, 202-5	68
2156	PRIMARY AND SECONDARY SJOJREN'S SYNDROME. <b>1984</b> , 324, 730-731	
2155	Bronchiolitis obliterans complicating bone marrow transplantation. <b>1985</b> , 87, 828-30	46

2154	Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. <b>1985</b> , 40, 504-9	88
2153	Pulmonary complications of bone marrow transplantation. <b>1985</b> , 87, 237-46	276
2152	Immunological features of polymyositis/dermatomyositis. <b>1985</b> , 8, 267-93	17
2151	Bone marrow transplantation. <b>1985</b> , 2, 261-96	4
2150	Familial erythrophagocytic lymphohistiocytosis. A neuropathologic study. <b>1985</b> , 66, 140-4	17
2149	Mast cell depletion in murine chronic graft-versus-host disease. <b>1985</b> , 84, 246-8	28
2148	Human cutaneous graft-versus-host disease. <b>1985</b> , 85, 124s-128s	46
2147	Graft-versus-host disease. <b>1985</b> , 88, 193-214	96
2146	Graft-versus-host disease in murine bone marrow transplantation. I. Modification of GVHD by preimmunization of recipients with spleen cells of primary recipients undergoing GVHD. <b>1985</b> , 11, 281-91	3
2145	Graft-versus-host disease in murine bone marrow transplantation. II. Modulation of acute and chronic GVHD in mice receiving bone marrow allografts pretreated with immunosuppressive factor derived from a human T cell line. <b>1985</b> , 11, 293-9	6
2144	Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. <b>1985</b> , 94, 73-84	96
2143	Oral condition of patients with leukemia and severe aplastic anemia. Follow-up 1 year after bone marrow transplantation. <b>1985</b> , 60, 498-504	38
2142	Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. <b>1985</b> , 5, 1076-82	125
2141	Bronchiolitis obliterans after bone marrow transplantation. <b>1985</b> , 18, 325-8	16
2140	Lymphoid interstitial pneumonia after allogeneic bone marrow transplantation. A possible manifestation of chronic graft-versus-host disease. <b>1985</b> , 55, 1-9	70
2139	Bullous Scleroderma-like Changes in Chronic Graft-vs-Host Disease. <b>1985</b> , 121, 1189	17
2138	The pathogenesis of primary biliary cirrhosis. <b>1985</b> , 8, 293-305	12
2137	Bone-marrow grafting induces acetylcholine receptor antibody formation. <b>1985</b> , 1, 978	22

2136	Pulmonary disease in the immunocompromised host. 1. <b>1985</b> , 60, 473-87	139
2135	Routine measurement of thyroid hormones and FSH in infertility not worthwhile. <b>1985</b> , 1, 977-8	6
2134	Hepatic disease in the Spanish toxic oil syndrome. A thirty months follow-up study. <b>1986</b> , 3, 59-65	8
2133	Diffuse intestinal ulceration after marrow transplantation: a clinicopathologic study of 13 patients. <b>1986</b> , 17, 621-33	80
2132	Factitious hyponatremia in a patient with cholestatic jaundice following bone marrow transplantation. <b>1986</b> , 18, 158-9	12
2131	The Occurrence of Malignant Tumors in Immunosuppressed States <sup>1</sup> . <b>1986</b> , 37, 259-300	28
2130	Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. <b>1986</b> , 105, 20-6	195
2129	Intestinal and hepatic complications of human bone marrow transplantation. Part I. <b>1986</b> , 90, 460-77	233
2128	Bone marrow transplantation. <b>1986</b> , 66, 589-601	8
2127	Intestinal and hepatic complications of human bone marrow transplantation. Part II. <b>1986</b> , 90, 770-84	145
2126	Satellite cell necrosis in two cases with dermatomyositis. <b>1986</b> , 13, 208-12	1
2125	Aplastic anemia: analysis of two methods of treatment. <b>1986</b> , 16, 470-4	1
2124	The impact of leukemia status at the time of HLA-identical sibling marrow transplantation on subsequent complication rate and survival of adults with acute leukemia. <b>1986</b> , 16, 462-9	7
2123	Bone marrow transplantation for good-risk patients with leukemia in a university affiliated hospital. <b>1986</b> , 22, 365-73	
2122	Allogeneic bone marrow transplantation in leukemia patients. <b>1986</b> , 10, 1-52	4
2121	Mononuclear cell subpopulations in the skin defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. <b>1986</b> , 114, 145-60	33
2120	Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. <b>1986</b> , 63, 671-9	57
2119	Intrahepatic bile duct injury following bone marrow transplantation. Analysis of pathological features based on three-dimensional and histochemical observation. <b>1986</b> , 36, 1793-806	

2118	Hemopoietic progenitor cell function after HLA-identical sibling bone marrow transplantation: influence of chronic graft-versus-host disease. <b>1986</b> , 4, 203-20	13
2117	Acute and chronic graft-versus-host disease in man. <b>1986</b> , 4 Suppl 1, 42-93	104
2116	Leukemia prevention and long-term survival of AKR mice transplanted with MHC-matched or MHC-mismatched bone marrow. <b>1986</b> , 101, 476-92	4
2115	Acute folic acid deficiency after bone marrow transplantation. <b>1986</b> , 64, 423-32	0
2114	Lung diseases after bone marrow transplantation. Results of a clinical, radiological, histological, immunological and lung function study. <b>1986</b> , 64, 595-614	10
2113	Bone marrow transplantation and the lung. <b>1986</b> , 41, 497-502	27
2112	Dermatologic Problems in the Intensive Care Unit: Part III. <b>1986</b> , 1, 156-170	
2111	Leukocytes in Transfusion Medicine [An Overview of Functions and Clinical Implications. <b>1987</b> , 17-35	1
2110	Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. <b>1987</b> , 317, 1618-24	190
2109	Systemic sclerosis: reasons to be optimistic. <b>1987</b> , 26, 241-3	
2108	A comparative study of T-cell depleted and non-depleted marrow transplantation for hematological malignancy. <b>1987</b> , 17, 16-23	9
2107	Cirrhosis as a consequence of graft-versus-host disease. <b>1987</b> , 92, 513-9	43
2106	Cutaneous graft versus host disease. <b>1987</b> , 295, 401-2	12
2105	Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin. <b>1987</b> , 106, 56-8	15
2104	Human marrow transplantation: an immunological perspective. <b>1987</b> , 40, 379-438	91
2103	The Role of Surgical Pathology in the Management of the Transplant Patient. <b>1987</b> , 18, 849-851	
2102	Use of Human Minor Salivary Glands in Basic and Applied Secretion Research. <b>1987</b> , 66, 654-659	17
2101	Neuroendocrine and bone marrow factors for control of marrow transplantation and tissue regeneration. <b>1987</b> , 496, 27-38	5



2100	Cutaneous mucinosis in the toxic oil syndrome. <b>1987</b> , 16, 139-40	16
2099	Localized oral and perioral lesions in chronic graft-versus-host disease. <b>1987</b> , 16, 138-9	4
2098	Use of human minor salivary glands in basic and applied secretion research. <b>1987</b> , 66 Spec No, 654-9	17
2097	Bone-marrow transplantation and toxoplasmic retinochoroiditis. <b>1987</b> , 225, 239-43	12
2096	Expression of restricted immunoglobulin isotypes in plasmacellular hyperplasia after allogeneic bone marrow transplantation. <b>1987</b> , 26, 409-16	9
2095	Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjögren syndrome and scleroderma. <b>1987</b> , 66, 45-47	47
2094	Bone marrow transplantation for myelodysplastic syndromes. <b>1988</b> , 69, 29-33	32
2093	Intrahepatic periductal glands in graft-versus-host disease. <b>1988</b> , 38, 281-9	1
2092	A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. <b>1988</b> , 8, 463-70	147
2091	Polyclonal activation and experimental nephropathies. <b>1988</b> , 34, 141-50	33
2090	Proliferation of pulmonary macrophages during the early phase of an acute graft-versus-host reaction in mice. <b>1988</b> , 14, 781-96	4
2089	An overview of bone marrow transplantation. <b>1988</b> , 4, 3-8	6
2088	High incidence of early leukemic relapse in patients given cyclosporin and T cell depleted HLA-identical sibling marrow transplants for acute leukemia in first remission. <b>1988</b> , 18, 587-93	4
2087	A prospective randomised trial of cyclosporin versus methotrexate after HLA-identical sibling marrow transplantation for patients with acute leukemia in first remission: analysis 2.5 years after last patient entry. <b>1988</b> , 18, 594-9	10
2086	Late effects of antileukemic treatment. <b>1988</b> , 35, 815-33	43
2085	Graft-versus-host disease in the central nervous system. A real entity?. <b>1988</b> , 89, 543-6	59
2084	Neurologic Complications of Graft-Versus-Host Disease. <b>1988</b> , 6, 389-403	29
2083	Critical Care Issues in Bone Marrow Transplantation. <b>1988</b> , 4, 147-166	5

2082	Autoantibody formation after bone marrow transplantation. Comparison between acetylcholine receptor antibodies and other autoantibodies and analysis of HLA and Gm markers. <b>1989</b> , 29, 128-34	19
2081	Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. <b>1989</b> , 320, 828-34	277
2080	Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. <b>1989</b> , 321, 784-9	349
2079	Carcinoma of breast and scleroderma: four further cases and a literature review. <b>1989</b> , 28, 65-9	54
2078	Ocular complications of bone marrow transplantation. <b>1989</b> , 3 ( Pt 3), 271-6	54
2077	Bronchiolitis obliterans. <b>1989</b> , 167, 69-93	64
2076	Histocompatibility antigen DR4 is associated with chronic graft-versus-host disease in the south Wales population. <b>1989</b> , 73, 424	11
2075	The pathogenesis of graft-versus-host reaction in the intrahepatic bile duct. An immunohistochemical study. <b>1989</b> , 39, 648-55	2
2074	Hypoglycaemia induced by antibodies to insulin receptor following a bone marrow transplantation in an immunodeficient child. <b>1989</b> , 32, 167-72	13
2073	Noninfectious causes of fever and a rash. <b>1989</b> , 28, 145-56	1
2072	Lymphocytic infiltrations of lip salivary glands in bone marrow recipients. A model for the development of the histopathological changes in Sjögren's syndrome?. <b>1989</b> , 2, 579-83	9
2071	The pathobiology of chronic rejection. <b>1989</b> , 3, 131-152	8
2070	Mesangiolytic glomerulopathy in a bone marrow allograft recipient. <b>1989</b> , 20, 290-2	12
2069	Oral mucous membrane lesions in children treated with bone marrow transplantation. <b>1989</b> , 97, 268-77	1
2068	Lichen planus and liver diseases: a multicentre case-control study. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED). <b>1990</b> , 300, 227-30	104
2067	Secondary biliary cirrhosis as a consequence of graft-versus-host disease. <b>1990</b> , 98, 223-5	22
2066	Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. <b>1990</b> , 76, 128-34	37
2065	An unusual presentation of chronic graft-versus-host disease in an unrelated bone marrow transplantation. <b>1990</b> , 69, 581-4	3

2064	Graft-versus-host disease of the intestine. <b>1990</b> , 12, 283-99	8
2063	Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis. <b>1990</b> , 33, 511-9	19
2062	Graft-versus-host disease--a histological perspective. <b>1990</b> , 4, 196-203	6
2061	Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission. <b>1990</b> , 19, 889-97	53
2060	Immune Recovery After Bone Marrow Transplantation. <b>1990</b> , 4, 659-675	41
2059	Skin Lesions in Transplant Patients. <b>1990</b> , 8, 313-325	5
2058	Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. <b>1990</b> , 162, 496-500	101
2057	Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. <b>1990</b> , 322, 485-94	211
2056	Bone marrow transplantation in patients with thalassemia. <b>1990</b> , 322, 417-21	501
2055	Neuropathologic findings after bone marrow transplantation: an autopsy study. <b>1990</b> , 21, 630-9	104
2054	Diffuse biliary tract involvement mimicking primary sclerosing cholangitis after bone marrow transplantation. <b>1990</b> , 10, 23-8	12
2053	Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome. <b>1991</b> , 119, 907-12	42
2052	L3T4+ T cells induce hepatic lesions resembling primary biliary cirrhosis in mice with graft-versus-host reactions due to major histocompatibility complex class II disparity. <b>1991</b> , 59, 449-61	17
2051	Chronic myeloid leukaemia treated by allogeneic bone marrow transplantation from histocompatible sibling donors--an invariably fatal malignancy rendered highly curable. <b>1991</b> , 21, 408-13	1
2050	A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. <b>1991</b> , 21, 850-6	25
2049	Optic disc edema after bone marrow transplantation. Possible role of cyclosporine toxicity. <b>1991</b> , 98, 1294-301	62
2048	Polymyositis: a manifestation of chronic graft-versus-host disease. <b>1991</b> , 25, 560-2	26
2047	Manifestations of Graft-Versus-Host Disease following Allogenic Bone Marrow Transplantation. <b>1991</b> , 1, 28-32	27

2046	A clinical review: cutaneous manifestations of acute and chronic graft-versus-host disease following bone marrow transplantation. <b>1991</b> , 18, 11-7	14
2045	Suppressor function of hepatic mononuclear inflammatory cells during murine chronic graft-vs-host disease. I. Macrophage-enriched cells mediate suppression in the liver. <b>1991</b> , 132, 256-68	9
2044	Graft-versus-host disease. <b>1991</b> , 324, 667-74	1053
2043	Chronic cutaneous graft-versus-host disease: successful treatment with UVB. <b>1991</b> , 125, 498-9	9
2042	Rheumatological manifestations of the leukaemias and graft versus host disease. <b>1991</b> , 5, 231-51	23
2041	Late renal dysfunction in adult survivors of bone marrow transplantation. <b>1991</b> , 67, 2795-800	90
2040	Autoantibody formation after bone marrow transplantation: a comparison between autologous and allogeneic grafts. <b>1991</b> , 11, 7-12	14
2039	Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. <b>1992</b> , 166, 1021-8	69
2038	Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. <b>1992</b> , 116, 624-9	75
2037	Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. <b>1992</b> , 26, 49-55	120
2036	A comparative immunological analysis of the oral mucosa in chronic graft-versus-host disease and oral lichen planus. <b>1992</b> , 37, 539-47	43
2035	SCID mice in the study of human autoimmune diseases. <b>1992</b> , 14, 159-77	8
2034	Chronic graft-versus-host disease and pulmonary function. <b>1992</b> , 14, 141-8	16
2033	Vesicular graft-versus-host disease. <b>1992</b> , 31, 509-10	12
2032	The hu-PBL-SCID mouse model. Long-term human serologic evolution associated with the xenogeneic transfer of human peripheral blood leukocytes into SCID mice. <b>1992</b> , 139, 468-77	37
2031	Suppressor function of liver mononuclear cells isolated during murine chronic graft-vs-host disease. II. Role of prostaglandins and interferon-gamma. <b>1992</b> , 140, 54-66	14
2030	Vanishing Bile Duct Syndrome: A Possible Mechanism for Intrahepatic Cholestasis in Hodgkin's Lymphoma. <b>1993</b> , 17, 70-77	106
2029	Autoimmunity, hyporeactivity to T cell mitogens and lymphoproliferative disorders following neonatal induction of transplantation tolerance in mice. <b>1993</b> , 23, 3011-20	3

2028	Acyclovir influence on graft versus host disease. <b>1993</b> , Suppl 1, 112-7	2
2027	Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. <b>1993</b> , 1, 195-9	70
2026	Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. <b>1993</b> , 83, 118-24	72
2025	[Immunologic aspects of bone marrow transplantation]. <b>1993</b> , 36, 339-73	
2024	Occurrence of primary biliary cirrhosis, CREST syndrome and Sjögren's syndrome in a patient with HTLV-I-associated myelopathy. <b>1993</b> , 116, 47-51	4
2023	Unrelated volunteer donor bone marrow transplantation: the current state of the art. <b>1993</b> , 23, 447-9	1
2022	Unrelated volunteer bone marrow transplantation: initial experience at St Vincent's Hospital, Sydney. <b>1993</b> , 23, 450-7	5
2021	Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. <b>1993</b> , 329, 840-4	184
2020	Chronic graft-versus-host disease with follicular involvement. <b>1993</b> , 20, 242-6	13
2019	Clinical course of late-onset bone marrow transplant nephropathy. <b>1993</b> , 64, 626-35	63
2018	Bone Marrow Transplantation: A Review. <b>1993</b> , 2, 75-98	2
2017	Okuläre Komplikationen bei Langzeitüberlebenden nach Knochenmarktransplantation - Eine prospektive Studie mit 21 Patienten. <b>1993</b> , 202, 110-115	5
2016	Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. <b>1993</b> , 119, 207-14	142
2015	Transfer of human myocarditis into severe combined immunodeficiency mice. <b>1994</b> , 75, 156-64	47
2014	Bone marrow transplantation. <b>1994</b> , 330, 827-38	579
2013	Videofluoroscopy of the pharynx and esophagus in chronic graft-versus-host disease. <b>1994</b> , 19, 191-4	11
2012	Total lymphoid irradiation prior to bone marrow transplantation for severe aplastic anemia: Analysis of 20 cases. <b>1994</b> , 2, 44-49	
2011	The role of major histocompatibility complex and non-major histocompatibility complex encoded antigens in generation of bile duct lesions during hepatic graft-vs.-host responses mediated by helper or cytotoxic T cells. <b>1994</b> , 19, 980-988	9

2010	Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. <b>1994</b> , 45, 240-3	18
2009	An apparent unusual relationship between rampant caries and the oral mucosal manifestations of chronic graft-versus-host disease. <b>1994</b> , 78, 267-72	11
2008	Acute renal failure in the setting of bone marrow transplantation. <b>1994</b> , 46, 1443-58	120
2007	Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. <b>1994</b> , 88, 64-71	63
2006	Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. <b>1994</b> , 330, 100-6	428
2005	Gastrointestinal disease in the immunocompromised patient. <b>1994</b> , 25, 1123-40	61
2004	Scleroderma-like diseases. <b>1994</b> , 12, 437-48	4
2003	Increasing incidence of adenovirus disease in bone marrow transplant recipients. <b>1994</b> , 169, 775-81	299
2002	Facial erythema and pigmentation as an initial manifestation of chronic graft-versus-host disease. <b>1994</b> , 21, 185-8	2
2001	Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. <b>1994</b> , 120, 993-8	95
2000	Ursodiol for hepatobiliary disorders. <b>1994</b> , 121, 207-18	58
1999	Immunohistochemical identification of perforin-positive cytotoxic lymphocytes in graft-versus-host disease. <b>1995</b> , 103, 324-9	18
1998	Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. <b>1995</b> , 35, 891-8	13
1997	Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. <b>1995</b> , 15, 137-44	65
1996	New and experimental therapies for treating graft-versus-host disease. <b>1995</b> , 9, 117-33	21
1995	Cutaneous Chronic Graft-vs-Host Disease and Hepatitis C Virus. <b>1995</b> , 131, 853	
1994	Graft-versus-host reaction and rejection after experimental small-bowel transplantation. Minireview based on a doctoral thesis. <b>1995</b> , 100, 53-92	0
1993	The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. <b>1995</b> , 26, 668-75	151

1992	Degeneration of intrahepatic bile duct with lymphocyte infiltration into biliary epithelial cells in biliary atresia. <b>1995</b> , 30, 515-8	63
1991	Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. <b>1995</b> , 345, 1398-402	229
1990	Pulmonary embolism with bone fragments following vertebral body marrow infusion for tolerance induction. <b>1996</b> , 5, 513-6	2
1989	Pseudomembranous conjunctivitis following bone marrow transplantation: immunopathological and ultrastructural study of one case. <b>1996</b> , 27, 307-9	18
1988	High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group. <b>1996</b> , 22, 271-7	25
1987	Pulmonary Embolism with Bone Fragments following Vertebral Body Marrow Infusion for Tolerance Induction. <b>1996</b> , 5, 513-516	3
1986	Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia. <b>1996</b> , 92, 49-54	19
1985	Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors. <b>1996</b> , 16, 107-14	11
1984	Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). <b>1996</b> , 38, 169-76	10
1983	Pulmonary function changes in long-term survivors of bone marrow transplantation. <b>1996</b> , 36, 67-75	54
1982	Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. <b>1996</b> , 134, 848-854	27
1981	Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. <b>1996</b> , 134, 780-783	7
1980	Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. <b>1996</b> , 94, 65-72	82
1979	Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). <b>1996</b> , 95, 715-23	76
1978	Electron-microscopic study of sclerodermatous chronic graft-versus-host disease. <b>1996</b> , 35, 862-6	16
1977	Sclerodermatous changes of chronic graft-versus-host-disease treated with puva. <b>1996</b> , 35, 656-8	4
1976	Final height of patients who underwent bone marrow transplantation during childhood. <b>1996</b> , 74, 437-40	36
1975	Chronic polyarthritis and graft-versus-host disease. <b>1996</b> , 35, 297-8	1

1974	Langerhans' cells are depleted in chronic graft versus host disease. <b>1997</b> , 50, 305-9	9
1973	Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. <b>1997</b> , 24, 539-43	39
1972	Graft-vs.-host disease. <b>1997</b> , 8, 201-16	95
1971	Pulmonary complications and respiratory function changes after bone marrow transplantation in children. <b>1997</b> , 10, 2301-6	41
1970	Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+ B cells and occurrence of graft-versus-host disease. <b>1997</b> , 29, 184-8	12
1969	Immunohistochemical study of skin lesions in acute and chronic graft versus host disease following bone marrow transplantation. <b>1997</b> , 21, 23-34	31
1968	Gonadal function after bone marrow transplantation for acute leukemia during childhood. <b>1997</b> , 130, 210-6	176
1967	Hepatobiliary graft-versus-host disease manifested by common and hepatic biliary duct obstruction. <b>1997</b> , 58, 494-7	8
1966	Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. <b>1997</b> , 89, 4531-4536	1001
1965	[Intrathecal immunoglobulin synthesis evaluation in bone marrow transplantation]. <b>1997</b> , 55, 801-11	0
1964	Successful Correction of Hemophagocytic Lymphohistiocytosis With Related or Unrelated Bone Marrow Transplantation. <b>1997</b> , 89, 3857-3863	88
1963	Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant. <b>1997</b> , 89, 3864-3872	180
1962	Treatment of Chronic Graft-Versus-Host Disease With Clofazimine. <b>1997</b> , 89, 2298-2302	72
1961	Donor Leukocyte Infusions Are Effective in Relapsed Multiple Myeloma After Allogeneic Bone Marrow Transplantation. <b>1997</b> , 90, 4206-4211	266
1960	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <b>1997</b> , 90, 4705-4709	288
1959	[Blood-brain barrier evaluation in bone marrow transplantation]. <b>1997</b> , 55, 812-8	1
1958	Cutaneous manifestations of chronic graft-versus-host disease. <b>1997</b> , 38, 53-62; quiz 63-4	37
1957	Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis. <b>1997</b> , 20, 107-12	34



1956	Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. <b>1997</b> , 20, 773-7	26
1955	[Transplantation of hematopoietic stem cells. I: Definitions, principle indications, complications]. <b>1997</b> , 92, 480-91, 505	4
1954	Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. <b>1997</b> , 99, 36-40	19
1953	Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. <b>1997</b> , 98, 750-9	37
1952	Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. <b>1998</b> , 18, 193-201	19
1951	Complete heart block in association with graft-versus-host disease. <b>1998</b> , 21, 85-8	19
1950	Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. <b>1998</b> , 21, 43-9	24
1949	Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. <b>1998</b> , 21, 711-9	44
1948	Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. <b>1998</b> , 21, 1055-61	61
1947	Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. <b>1998</b> , 21, 995-1003	202
1946	Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. <b>1998</b> , 22, 131-6	30
1945	The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. <b>1998</b> , 22, 139-46	28
1944	High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. <b>1998</b> , 22, 259-64	47
1943	A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. <b>1998</b> , 22, 273-6	40
1942	Outcome of acute lymphoblastic leukaemia in Danish children after allogeneic bone marrow transplantation. Superior survival following transplantation with matched unrelated donor grafts. <b>1998</b> , 22, 325-30	18
1941	Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haematopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. <b>1998</b> , 22, 541-5	18
1940	Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. <b>1998</b> , 22, 755-61	146
1939	A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. <b>1998</b> , 22, 1145-51	157

1938	Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. <b>1998</b> , 102, 860-71	85
1937	Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. <b>1998</b> , 100, 198-206	51
1936	Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Soci�t� Fran�aise de Greffe de Moelle study. <b>1998</b> , 102, 656-65	37
1935	Graft-versus-host reactions in dermatology. <b>1998</b> , 38, 369-92; quiz 393-6	103
1934	Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. <b>1998</b> , 86, 183-7	30
1933	Avascular necrosis following bone marrow transplantation: a case-control study. <b>1998</b> , 22, 67-71	82
1932	Membranous nephropathy with chronic graft-versus-host disease in a bone marrow transplant recipient. <b>1998</b> , 80, 371-2	28
1931	T-Cell Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. <b>1998</b> , 91, 1083-1090	195
1930	Hurler Syndrome: II. Outcome of HLA-Genotypically Identical Sibling and HLA-Haploidentical Related Donor Bone Marrow Transplantation in Fifty-Four Children. <b>1998</b> , 91, 2601-2608	295
1929	Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia. <b>1998</b> , 92, 4072-4079	207
1928	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <b>1998</b> , 92, 1910-1917	129
1927	High Risk of Chronic Graft-Versus-Host Disease in Unmanipulated Allogeneic Peripheral Blood Stem Cell Transplantation. <b>1998</b> , 92, 2973-2975	5
1926	Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host Disease. <b>1998</b> , 92, 3098-3104	298
1925	Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. <b>1999</b> , 17, 806-12	76
1924	Total body irradiation, thiotepe, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings. <b>1999</b> , 17, 1838-46	43
1923	Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821. <b>1999</b> , 17, 2144-52	35
1922	Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. <b>1999</b> , 17, 1234	110
1921	Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management. <b>1999</b> , 93, 1127-1136	103

1920	T-Cell Depletion Plus Salvage Immunotherapy With Donor Leukocyte Infusions as a Strategy to Treat Chronic-Phase Chronic Myelogenous Leukemia Patients Undergoing HLA-Identical Sibling Marrow Transplantation. <b>1999</b> , 94, 434-441	80
1919	Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation. <b>1999</b> , 94, 455-464	169
1918	Dry eye after haematopoietic stem cell transplantation. <b>1999</b> , 83, 1125-30	160
1917	Late pulmonary sequelae after childhood bone marrow transplantation. <b>1999</b> , 54, 131-5	61
1916	Ovarian function after bone marrow transplantation performed before menarche. <b>1999</b> , 80, 452-4	43
1915	From autoimmunity to stem cell transplantation. <b>1999</b> , 30, 159-72	5
1914	Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. <b>1999</b> , 13, 330-5	85
1913	Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. <b>1999</b> , 13, 512-9	14
1912	Infections in adults undergoing unrelated donor bone marrow transplantation. <b>1999</b> , 104, 560-8	93
1911	Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. <b>1999</b> , 106, 1052-8	61
1910	Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow. <b>1999</b> , 107, 429-40	19
1909	Henoch-Sch��lein purpura induced by clarithromycin. <b>1999</b> , 38, 706-8	21
1908	Superficial cutaneous sporotrichosis in specific anergic patient. <b>1999</b> , 38, 700-3	8
1907	Lichen sclerosus et atrophicus in sclerodermatous chronic graft-versus-host disease. <b>1999</b> , 38, 708-11	17
1906	Vegetative pyoderma gangrenosum: an unusual presentation. <b>1999</b> , 38, 703-6	11
1905	Immune reconstitution following allogeneic peripheral blood stem cell transplants. <b>1999</b> , 23, 335-46	62
1904	A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. <b>1999</b> , 23, 355-61	89
1903	Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells. <b>1999</b> , 23, 1061-70	7

1902	Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. <b>1999</b> , 23, 1291-5	24
1901	Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations. <b>1999</b> , 24, 173-7	16
1900	Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. <b>1999</b> , 24, 823-30	113
1899	A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. <b>1999</b> , 24, 831-6	41
1898	Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. <b>1999</b> , 30, 71-8	59
1897	Health-related quality of life in pediatric bone marrow transplant survivors: according to whom?. <b>1999</b> , 12, 46-51	132
1896	13-cis-retinoic acid-induced eosinophilia following autologous bone marrow transplantation for neuroblastoma. <b>1999</b> , 32, 308-10	1
1895	The use of oral pilocarpine in xerostomia and Sjögren's syndrome. <b>1999</b> , 28, 360-7	35
1894	Pathophysiology and treatment of graft-versus-host disease. <b>1999</b> , 13, 1091-112, viii-ix	149
1893	Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. <b>1999</b> , 91, 106-16	72
1892	In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. <b>1999</b> , 32, 317-25	24
1891	Long-term extracorporeal photoimmunotherapy for treatment of chronic cutaneous graft-versus-host disease: observations in four patients. <b>1999</b> , 198, 370-4	15
1890	Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. <b>2000</b> , 18, 537-46	330
1889	Red blood cell phenotyping is a sensitive technique for monitoring chronic myeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion. <b>2000</b> , 108, 116-25	21
1888	A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. <b>2000</b> , 25, 1129-36	102
1887	Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation. <b>2000</b> , 25, 1223-8	10
1886	Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. <b>2000</b> , 26, 17-22	15
1885	Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. <b>2000</b> , 26, 161-7	43

1884	High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. <b>2000</b> , 26, 333-8	8
1883	Donor leukocyte infusions in acute lymphocytic leukemia. <b>2000</b> , 26, 511-6	185
1882	First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. <b>2000</b> , 26, 673-5	19
1881	Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. <b>2000</b> , 26, 615-20	67
1880	Response to thalidomide therapy in refractory chronic graft-versus-host disease. <b>2000</b> , 26, 865-9	59
1879	Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. <b>2000</b> , 26, 985-91	46
1878	Donor leukocyte infusions for multiple myeloma. <b>2000</b> , 26, 1179-84	146
1877	Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells. <b>2000</b> , 26, 1325-31	7
1876	Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. <b>2000</b> , 26, 1333-8	195
1875	Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. <b>2000</b> , 26, 1317-23	65
1874	Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. <b>2000</b> , 14, 2052-8	5
1873	The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. <b>2000</b> , 25, 411-7	55
1872	Criteria for assessing chronic GVHD. <b>2000</b> , 25, 575	22
1871	Chronic graft-versus-host disease: is there an alternative to the conventional treatment?. <b>2000</b> , 25, 689-96	33
1870	A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study. <b>2000</b> , 25 Suppl 2, S27-31	13
1869	Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. <b>2000</b> , 32, 1265-71	92
1868	Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. <b>2000</b> , 96, 2391-2398	88
1867	Late effects of treatment in survivors of childhood acute myeloid leukemia. <b>2000</b> , 18, 3273-9	170

1866	Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. <b>2000</b> , 95, 1572-1579	135
1865	Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. <b>2000</b> , 18, 3031-7	247
1864	Diagnosis of gastrointestinal graft-versus-host disease. <b>2000</b> , 95, 3034-8	105
1863	Dendritic cell dynamics in the liver and hepatic lymph. <b>2000</b> , 197, 83-136	41
1862	Chronic graft-versus-host disease. <b>2000</b> , 9, 339-46	12
1861	Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. <b>2000</b> , 9, 375-9	12
1860	Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. <b>2000</b> , 31, 927-35	146
1859	The pathology of bone marrow transplantation. <b>2000</b> , 6, 242-250	5
1858	The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey. <b>2000</b> , 6, 370-4	49
1857	Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. <b>2000</b> , 6, 361-9	85
1856	Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. <b>2000</b> , 6, 613-20	45
1855	De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival. <b>2000</b> , 6, 633-9	20
1854	Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. <b>2000</b> , 6, 321-6	29
1853	Hydroxychloroquine for the treatment of chronic graft-versus-host disease. <b>2000</b> , 6, 327-34	94
1852	Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. <b>2000</b> , 6, 7-83	34
1851	Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. <b>2000</b> , 9, 367-74	55
1850	Management of graft-versus-host disease in paediatric bone marrow transplant recipients. <b>2000</b> , 2, 29-55	18
1849	An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. <b>2000</b> , 2, 423-8	12

1848	Haematocolpos following allogeneic bone marrow transplantation for chronic myeloid leukaemia. <b>2001</b> , 108, 1309-1310	6
1847	The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. <b>2001</b> , 7, 31-8	45
1846	Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. <b>2001</b> , 7, 265-73	113
1845	Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. <b>2001</b> , 7, 620-30	56
1844	Redefining 'self': the role of microflora (commensals) mismatch in the development of GvHD after allogeneic stem cell transplantation and some possible remedies. <b>2001</b> , 56, 448-50	
1843	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. <b>2001</b> , 7, 561-7	20
1842	Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. <b>2001</b> , 7, 568-75	49
1841	Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <b>2001</b> , 7, 343-51	52
1840	Complement-mediated T-cell depletion of bone marrow: comparison of T10B9.1A-31 and Muromonab-Orthoclone OKT3. <b>2001</b> , 3, 467-81	18
1839	Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. <b>2001</b> , 3, 41-54	29
1838	Granzyme-B-containing lymphocyte involvement in epidermal injury in graft-versus-host disease. <b>2001</b> , 202, 94-8	16
1837	Multilayer amniotic membrane transplantation in severe ocular graft versus host disease. <b>2001</b> , 11, 183-6	37
1836	Transplante de medula �sea e transplante de sangue de cord� umbilical em pediatria. <b>2001</b> , 77, 345	3
1835	Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. <b>2001</b> , 19, 3675-84	158
1834	Chimerism analysis by lineage-specific fluorescent polymerase chain reaction in secondary graft failure after allogeneic stem cell transplantation. <b>2001</b> , 71, 374-80	7
1833	Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. <b>2001</b> , 97, 2957-61	327
1832	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <b>2001</b> , 97, 631-7	508
1831	How I treat chronic graft-versus-host disease. <b>2001</b> , 97, 1196-201	208



1830	Development of a prognostic model for grading chronic graft-versus-host disease. <b>2001</b> , 97, 1219-26	175
1829	No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. <b>2001</b> , 98, 1739-45	99
1828	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. <b>2001</b> , 98, 2332-8	202
1827	Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. <b>2001</b> , 27, 1221-5	38
1826	Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. <b>2001</b> , 80, 144-9	16
1825	Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. <b>2001</b> , 80, 430-5	29
1824	Cord blood transplantation from HLA-mismatched unrelated donors as a treatment for children with haematological malignancies. <b>2001</b> , 112, 981-7	27
1823	Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. <b>2001</b> , 114, 706-11	39
1822	Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. <b>2001</b> , 115, 935-44	52
1821	CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. <b>2001</b> , 41, 190-5	19
1820	Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. <b>2001</b> , 41, 1299-305	115
1819	Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. <b>2001</b> , 27, 73-8	74
1818	Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study. <b>2001</b> , 27, 27-33	20
1817	A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. <b>2001</b> , 27, 45-51	11
1816	Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT. <b>2001</b> , 27, 85-7	9
1815	Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. <b>2001</b> , 27, 1053-8	28
1814	Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. <b>2001</b> , 28, 181-5	120
1813	Chronic graft-versus-host disease: clinical manifestation and therapy. <b>2001</b> , 28, 121-9	187



1812	Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study. <b>2001</b> , 28, 537-43	11
1811	Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. <b>2001</b> , 28, 581-6	28
1810	The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia. <b>2001</b> , 28, 917-22	2
1809	Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. <b>2001</b> , 28, 1047-51	43
1808	Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. <b>2001</b> , 28, 1053-9	23
1807	Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. <b>2001</b> , 15, 1339-46	44
1806	Haematocolpos following allogeneic bone marrow transplantation for chronic myeloid leukaemia. <b>2001</b> , 108, 1309-10	2
1805	An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. <b>2001</b> , 66, 50-6	13
1804	Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. <b>2001</b> , 60, 577-84	189
1803	Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. <b>2001</b> , 27, 627-33	63
1802	Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. <b>2001</b> , 27, 727-30	38
1801	Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed?. <b>2001</b> , 120, 1900-6	62
1800	Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. <b>2001</b> , 32, 214-9	101
1799	Possible clinical benefits of the use of peripheral blood stem cells over bone marrow in the allogeneic transplantation setting for the treatment of childhood leukemia. <b>2001</b> , 31, 30-4	3
1798	Corneal perforation in chronic graft-versus-host disease. <b>2001</b> , 15, 111-3	8
1797	Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. <b>2001</b> , 27, 575-80	37
1796	Sporadic Burkitt's lymphoma presenting as solely orbital disease in a 78-year-old. <b>2001</b> , 15, 113-5	6
1795	Allogeneic BMT in patients above 45 years of age: a single center experience. <b>2001</b> , 27, 723-6	4

1794	Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. <b>2001</b> , 27, 977-82	49
1793	Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients. <b>2001</b> , 27, 999-1005	6
1792	Novel approaches to the treatment of chronic graft-versus-host disease. <b>2001</b> , 10, 909-23	5
1791	Clinical grading in chronic graft-versus-host disease: is it time for change?. <b>2002</b> , 43, 1211-20	12
1790	In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. <b>2002</b> , 11, 731-7	20
1789	Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. <b>2002</b> , 347, 36-42	69
1788	Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. <b>2002</b> , 16, 13-21	36
1787	A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. <b>2002</b> , 29, 373-7	81
1786	Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. <b>2002</b> , 29, 223-30	57
1785	Weight loss and malnutrition in patients with chronic graft-versus-host disease. <b>2002</b> , 29, 231-6	60
1784	Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <b>2002</b> , 8, 674-82	79
1783	Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. <b>2002</b> , 20, 4324-30	60
1782	Recipient cytokine genotypes for TNF-alpha and IL-10 and the minor histocompatibility antigens HY and CD31 codon 125 are not associated with occurrence or severity of acute GVHD in unrelated cord blood transplantation: a retrospective analysis. <b>2002</b> , 74, 1167-75	26
1781	Stem cell transplantation: supportive care and long-term complications. <b>2002</b> , 2002, 422-44	58
1780	Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. <b>2002</b> , 73, 1295-302	24
1779	Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. <b>2002</b> , 74, 236-43	13
1778	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <b>2002</b> , 100, 406-14	445
1777	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. <b>2002</b> , 100, 3128-34	163

1776	Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. <b>2002</b> , 99, 3524-9	179
1775	The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. <b>2002</b> , 99, 4200-6	355
1774	Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. <b>2002</b> , 99, 4350-6	112
1773	Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. <b>2002</b> , 99, 1943-51	190
1772	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <b>2002</b> , 100, 48-51	227
1771	Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. <b>2002</b> , 99, 2726-33	151
1770	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. <b>2002</b> , 100, 1192-200	175
1769	Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. <b>2002</b> , 100, 1977-83	197
1768	Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. <b>2002</b> , 100, 761-7	228
1767	Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. <b>2002</b> , 100, 2697-702	35
1766	Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. <b>2002</b> , 99, 806-14	86
1765	Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. <b>2002</b> , 138, 924-34	79
1764	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <b>2002</b> , 100, 415-9	358
1763	Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. <b>2002</b> , 8, 656-61	45
1762	Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity. <b>2002</b> , 8, 608-18	25
1761	Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. <b>2002</b> , 359, 2078-83	204
1760	Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. <b>2002</b> , 8, 47-56	71
1759	Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. <b>2002</b> , 8, 444-52	175

1758	Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. <b>2002</b> , 3, 333-40	102
1757	Correlation of mixed lymphocyte culture with chronic graft-versus-host disease following allogeneic stem cell transplantation. <b>2002</b> , 35, 567-72	2
1756	Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. <b>2002</b> , 20, 405-12	207
1755	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. <b>2002</b> , 94, 2409-15	99
1754	High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. <b>2002</b> , 95, 1076-84	132
1753	Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution. <b>2002</b> , 75, 318-23	16
1752	Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan. <b>2002</b> , 76, 354-9	3
1751	The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea. <b>2002</b> , 76, 267-71	9
1750	Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population. <b>2002</b> , 6, 319-26	7
1749	Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid. <b>2002</b> , 22, 514-7	12
1748	Nicotinic acetylcholine receptor mRNA in dorsal root ganglion neurons. <b>2002</b> , 22, 1-8	15
1747	Chronic demyelinating polyneuropathy in graft-versus-host disease following allogeneic bone marrow transplantation. <b>2002</b> , 22, 1-8	1
1746	Allogeneic bone marrow transplantation in children with acute lymphoblastic leukaemia in the first and second complete remission conditioned with fractionated total body irradiation and cyclophosphamide or etoposide. <b>2002</b> , 7, 117-125	1
1745	Chronic graft-versus-host disease and its management in children. <b>2002</b> , 7, 133-138	1
1744	Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. <b>2002</b> , 147, 433-41	21
1743	A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission. <b>2002</b> , 118, 140-3	45
1742	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. <b>2002</b> , 119, 144-54	67
1741	An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. <b>2002</b> , 119, 751-9	15

1740	Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. <b>2002</b> , 127, 553-9	30
1739	Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. <b>2002</b> , 8, 725-33	26
1738	Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. <b>2002</b> , 30, 189-94	77
1737	Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. <b>2002</b> , 30, 367-73	107
1736	Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. <b>2002</b> , 30, 421-6	32
1735	Cognitive and psychosocial functioning of pediatric hematopoietic stem cell transplant patients: a prospective longitudinal study. <b>2002</b> , 30, 609-17	60
1734	Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. <b>2002</b> , 30, 509-15	36
1733	Rapid-onset leucodrema associated with graft-versus-host disease. <b>2002</b> , 30, 705-6	11
1732	The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. <b>2002</b> , 30, 761-8	21
1731	Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. <b>2002</b> , 30, 899-903	74
1730	Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. <b>2002</b> , 16, 2423-8	84
1729	Hormone replacement therapy and chronic graft-versus-host disease activity in women treated with bone marrow transplantation for hematologic malignancies. <b>2002</b> , 966, 187-92	21
1728	A higher incidence of relapse for acute lymphocytic leukemia treated with allogeneic hematopoietic stem cell transplantation conditioned with BU-CY2 regimen. <b>2003</b> , 15, 213-216	
1727	Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. <b>2003</b> , 82, 621-7	24
1726	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. <b>2003</b> , 31, 873-80	17
1725	Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. <b>2003</b> , 31, 865-72	38
1724	Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. <b>2003</b> , 31, 959-65	15
1723	Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases. <b>2003</b> , 31, 934-40	4

1722	Systemic nocardiosis following allogeneic bone marrow transplantation. <b>2003</b> , 5, 16-20	45
1721	Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. <b>2003</b> , 5, 132-9	26
1720	Gingival lesions in a patient with chronic oral graft-versus-host disease: a case report. <b>2003</b> , 30, 375-8	2
1719	Post-transplantation chronic graft-versus-host disease with overlapping features similar to those of various collagen diseases. <b>2003</b> , 42, 292-4	12
1718	A pediatric case of sclerodermatous chronic graft-versus-host disease. <b>2003</b> , 20, 327-31	9
1717	The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis. <b>2003</b> , 120, 516-22	33
1716	T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. <b>2003</b> , 121, 109-18	49
1715	Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. <b>2003</b> , 122, 637-44	18
1714	Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. <b>2003</b> , 123, 119-26	17
1713	Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. <b>2003</b> , 31, 175-81	56
1712	Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. <b>2003</b> , 31, 253-61	120
1711	Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy. <b>2003</b> , 31, 291-4	23
1710	Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. <b>2003</b> , 31, 579-83	187
1709	Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. <b>2003</b> , 31, 877-87	25
1708	Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. <b>2003</b> , 32, 171-6	8
1707	Stem cell transplantation for myelofibrosis: a report from two Canadian centers. <b>2003</b> , 32, 35-40	66
1706	Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. <b>2003</b> , 32, 23-30	37
1705	Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study. <b>2003</b> , 32, 257-64	16

1704	Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. <b>2003</b> , 32, 237-42	15
1703	Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. <b>2003</b> , 32, 1077-84	15
1702	Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. <b>2003</b> , 32, 1071-5	11
1701	Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. <b>2003</b> , 32, 1159-63	82
1700	Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. <b>2003</b> , 17, 869-75	113
1699	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. <b>2003</b> , 17, 1930-3	36
1698	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. <b>2003</b> , 17, 2168-77	103
1697	Graft-vs.-Host Disease. 633-664	3
1696	Chronic graft-versus-host disease: a prospective cohort study. <b>2003</b> , 9, 38-45	73
1695	Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. <b>2003</b> , 9, 46-51	118
1694	Chronic graft-versus-host disease. <b>2003</b> , 9, 215-33	654
1693	Hematopoietic cell transplantation in the treatment of leukemia. <b>2003</b> , 19, 118-32	6
1692	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. <b>2003</b> , 9, 435-42	19
1691	Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. <b>2003</b> , 9, 649-56	21
1690	Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. <b>2003</b> , 9, 170-176	56
1689	Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. <b>2003</b> , 9, 206-212	61
1688	Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. <b>2003</b> , 28, 71-80	37
1687	Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. <b>2003</b> , 101, 407-14	486



1686	Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. <b>2003</b> , 101, 2137-43	315
1685	Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. <b>2003</b> , 21, 3060-5	55
1684	Chronic graft-vs-host disease. <b>2003</b> , 290, 2599-603	51
1683	Polymyositis as a manifestation of chronic graft-versus-host disease. <b>2003</b> , 42, 34-9	78
1682	Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. <b>2003</b> , 18, 1410-6	45
1681	Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. <b>2003</b> , 21, 1480-4	148
1680	CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation. <b>2003</b> , 44, 1509-13	7
1679	Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. <b>2003</b> , 168, 208-14	191
1678	Abstract. <b>2003</b> , 21, 1-108	24
1677	Pentostatin for the treatment of chronic graft-versus-host disease in children. <b>2003</b> , 25, 584-8	42
1676	Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. <b>2003</b> , 8, 303-11	26
1675	Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. <b>2003</b> , 139, 8-18	85
1674	Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. <b>2003</b> , 31, 1044-1050	67
1673	Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. <b>2003</b> , 102, 394-403	269
1672	Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. <b>2003</b> , 102, 802-9	122
1671	Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. <b>2003</b> , 102, 4236-42	107
1670	Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. <b>2003</b> , 102, 1217-23	101
1669	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. <b>2003</b> , 102, 470-6	169



1668	Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. <b>2003</b> , 101, 4711-3	69
1667	Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. <b>2003</b> , 44, 1888-96	90
1666	Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. <b>2004</b> , 351, 2276-85	956
1665	Fanconi anemia: contribution of molecular analyses to the identification of bone marrow graft donors and the study of chimerism in grafted patients. <b>2004</b> , 8, 268-75	
1664	Pleural effusions in hematologic malignancies. <b>2004</b> , 125, 1546-55	156
1663	Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. <b>2004</b> , 104, 1923-30	569
1662	Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. <b>2004</b> , 5, 395-402	6
1661	Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies. <b>2004</b> , 18, 552-7	17
1660	Comparison of the outcomes of allogeneic bone marrow transplantation from partially mismatched related donors, matched sibling donors, and matched unrelated donors in Japanese pediatric patients: a single center result. <b>2004</b> , 8, 260-6	7
1659	Risk factors in pediatric stem cell transplantation for leukemia. <b>2004</b> , 8, 464-74	16
1658	Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. <b>2004</b> , 124, 629-35	32
1657	Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia. <b>2004</b> , 125, 58-63	22
1656	The London Cord Blood Bank: analysis of banking and transplantation outcome. <b>2004</b> , 125, 358-65	58
1655	Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. <b>2004</b> , 125, 480-93	29
1654	Chronic graft versus host disease. <b>2004</b> , 125, 435-54	134
1653	Unrelated cord blood transplantation after myeloablative conditioning in patients over the age of 45 years. <b>2004</b> , 126, 711-4	8
1652	Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. <b>2004</b> , 112, 605-14	74
1651	Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. <b>2004</b> , 33, 65-9	24

1650	Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens. <b>2004</b> , 33, 197-204	20
1649	Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. <b>2004</b> , 33, 535-42	8
1648	A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. <b>2004</b> , 33, 613-22	66
1647	Chronic graft-versus-host disease: where do we go from here?. <b>2004</b> , 33, 569-77	36
1646	Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. <b>2004</b> , 33, 759-64	52
1645	Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. <b>2004</b> , 33, 751-8	82
1644	Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. <b>2004</b> , 33, 605-11	63
1643	Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <b>2004</b> , 33, 789-92	9
1642	Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. <b>2004</b> , 33, 1115-21	10
1641	Mediastinal emphysema and bilateral pneumothoraces with chronic GVHD in patients after allogeneic stem cell transplantation. <b>2004</b> , 33, 1159-63	19
1640	Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation. <b>2004</b> , 33, 1097-105	29
1639	Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. <b>2004</b> , 33, 1143-50	72
1638	Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. <b>2004</b> , 34, 13-20	66
1637	Allogeneic myeloablative transplantation for patients aged 50 years and over. <b>2004</b> , 34, 29-35	28
1636	Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. <b>2004</b> , 34, 21-7	17
1635	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. <b>2004</b> , 34, 77-84	62
1634	Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. <b>2004</b> , 34, 63-8	14
1633	Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow. <b>2004</b> , 34, 345-50	12

1632	Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. <b>2004</b> , 34, 309-16	23
1631	Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. <b>2004</b> , 34, 433-8	9
1630	Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. <b>2004</b> , 34, 331-7	48
1629	Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. <b>2004</b> , 34, 795-8	18
1628	Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. <b>2004</b> , 34, 1039-45	6
1627	Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. <b>2004</b> , 18, 1013-9	41
1626	Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. <b>2004</b> , 18, 1789-97	97
1625	Evaluation of nail involvement in patients with chronic cutaneous graft versus host disease: a single-center study from Turkey. <b>2004</b> , 43, 176-80	17
1624	Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. <b>2004</b> , 73, 85-92	10
1623	Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. <b>2004</b> , 32, 397-407	342
1622	Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. <b>2004</b> , 32, 599-606	29
1621	CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <b>2004</b> , 32, 1097-102	34
1620	Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients. <b>2004</b> , 21, 81-94	9
1619	Chronic graft-versus-host disease: clinical features and grading systems. <b>2004</b> , 79, 216-20	12
1618	Diagnosis and clinical management of chronic graft-versus-host disease. <b>2004</b> , 79, 221-8	33
1617	Tacrolimus (FK506) for Graft-versus-host Disease after Allogeneic Blood Stem Cell Transplantation for Hematologic Malignancies. <b>2004</b> , 3, 2-4	
1616	Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. <b>2004</b> , 83, 101-6	56
1615	No predictive value of cytotoxic or helper T-cell precursor frequencies for outcome when analyzed from the graft after stem cell transplantation. <b>2004</b> , 83, 566-72	5

1614	Omission of day +11 methotrexate does not appear to influence incidence and severity of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <b>2004</b> , 16, 203-207	
1613	Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. <b>2004</b> , 75, 613-9	31
1612	Fatal coronary artery disease after unrelated donor bone marrow transplantation. <b>2004</b> , 79, 403-6	13
1611	High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis. <b>2004</b> , 17, 233-45	9
1610	Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. <b>2004</b> , 10, 106-15	39
1609	Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. <b>2004</b> , 10, 65-72	16
1608	Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. <b>2004</b> , 10, 171-7	11
1607	Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. <b>2004</b> , 10, 204-12	34
1606	Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. <b>2004</b> , 10, 310-9	36
1605	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. <b>2004</b> , 10, 698-708	94
1604	A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. <b>2004</b> , 10, 635-44	36
1603	Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. <b>2004</b> , 10, 867-76	42
1602	[Auto-immune-like disease post-bone marrow transplantation]. <b>2004</b> , 25, 514-23	5
1601	Hickman catheter site infections after allogeneic stem cell transplantation: a single-center experience. <b>2004</b> , 36, 1569-73	8
1600	Hickman catheter site infections after allogeneic stem cell transplantation: single-center experience. <b>2004</b> , 36, 3203-7	2
1599	Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study. <b>2004</b> , 77, 1854-8	33
1598	No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. <b>2004</b> , 78, 101-6	138
1597	Hepatic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. <b>2004</b> , 77, 1252-9	34

1596	Hematopoietic stem cell transplantation: a primer for the primary care physician. <b>2004</b> , 170, 1569-77	22
1595	Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. <b>2004</b> , 77, 1096-100	44
1594	Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. <b>2004</b> , 77, 526-31	23
1593	Allogeneic peripheral blood stem cell transplantation in children with homozygous beta-thalassemia and severe beta-thalassemia/hemoglobin E disease. <b>2004</b> , 26, 248-52	8
1592	Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. <b>2004</b> , 26, 81-90	69
1591	Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. <b>2004</b> , 103, 73-7	96
1590	Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. <b>2004</b> , 103, 489-91	91
1589	T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. <b>2004</b> , 103, 4322-9	33
1588	Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. <b>2004</b> , 103, 4056-61	82
1587	Duration of immunosuppressive treatment for chronic graft-versus-host disease. <b>2004</b> , 104, 3501-6	240
1586	Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. <b>2004</b> , 104, 3813-20	290
1585	Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. <b>2004</b> , 104, 3821-8	130
1584	Trefoil factor expression in biliary epithelium of graft-versus-host disease of the liver after allogeneic hematopoietic cell transplantation. <b>2005</b> , 80, 1099-104	2
1583	IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. <b>2005</b> , 79, 1615-22	33
1582	Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. <b>2005</b> , 80, 634-42	16
1581	Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients. <b>2005</b> , 80, 1376-82	25
1580	Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. <b>2005</b> , 27, 504-28	155
1579	A case of severe sclerodermatous chronic graft-versus-host disease: exposure to cement containing abundant silica may have been a relevant factor in scleroderma-like skin changes. <b>2005</b> , 32, 413-5	1

1578	Risk score for pediatric intensive care unit admission in children undergoing hematopoietic stem cell transplantation and analysis of predictive factors for survival. <b>2005</b> , 27, 526-31	26
1577	Peripheral dendritic cell chimerism in allogeneic hematopoietic stem cell recipients. <b>2005</b> , 80, 843-9	6
1576	Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation. <b>2005</b> , 10, 1-10	5
1575	Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. <b>2005</b> , 105, 3035-41	36
1574	Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. <b>2005</b> , 105, 548-51	62
1573	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. <b>2005</b> , 106, 2969-76	142
1572	Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. <b>2005</b> , 1054, 186-95	117
1571	Unrelated cord blood transplantation after myeloablative conditioning for adult patients with refractory anemia. <b>2005</b> , 81, 424-7	6
1570	Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. <b>2005</b> , 82, 449-55	24
1569	Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome. <b>2005</b> , 82, 66-71	3
1568	New approaches for preventing and treating chronic graft-versus-host disease. <b>2005</b> , 105, 4200-6	116
1567	Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. <b>2005</b> , 19, 798-803	13
1566	Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. <b>2005</b> , 129, 542-9	41
1565	Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. <b>2005</b> , 129, 631-43	98
1564	Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. <b>2005</b> , 35, 277-82	39
1563	Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. <b>2005</b> , 35, 455-61	16
1562	A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. <b>2005</b> , 35, 345-52	113
1561	Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. <b>2005</b> , 35, 467-71	47



1560	Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. <b>2005</b> , 35, 489-95	34
1559	Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease. <b>2005</b> , 35, 501-7	33
1558	Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. <b>2005</b> , 35, 755-61	14
1557	Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. <b>2005</b> , 35, 943-51	100
1556	Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. <b>2005</b> , 35, 1083-8	41
1555	Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. <b>2005</b> , 35, 1141-8	17
1554	Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. <b>2005</b> , 36, 39-50	82
1553	The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. <b>2005</b> , 36, 145-50	7
1552	Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. <b>2005</b> , 36, 163-9	45
1551	Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <b>2005</b> , 36, 343-8	43
1550	Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. <b>2005</b> , 36, 431-5	26
1549	Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. <b>2005</b> , 36, 437-41	77
1548	Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. <b>2005</b> , 36, 531-8	21
1547	IL-4-producing CD8(+) T cells may be an immunological hallmark of chronic GVHD. <b>2005</b> , 36, 639-47	11
1546	Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. <b>2005</b> , 36, 649-54	33
1545	Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation. <b>2005</b> , 36, 631-7	11
1544	Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. <b>2005</b> , 36, 683-9	41
1543	Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). <b>2005</b> , 36, 781-5	18

1542	Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. <b>2005</b> , 36, 867-72	42
1541	Unrelated donor stem cell transplantation in adult patients with thalassemia. <b>2005</b> , 36, 971-5	55
1540	Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). <b>2005</b> , 36, 1065-9	9
1539	Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. <b>2005</b> , 36, 1089-95	82
1538	Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. <b>2005</b> , 19, 396-401	97
1537	Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. <b>2005</b> , 19, 971-7	73
1536	A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. <b>2005</b> , 19, 1613-20	45
1535	Maternal microchimerism—Allogenic target of autoimmune disease or Normal Biology?. <b>2005</b> , 5, 325-338	1
1534	Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. <b>2005</b> , 33, 894-900	55
1533	Acute polymyositis after donor lymphocyte infusion. <b>2005</b> , 74, 166-8	13
1532	Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. <b>2005</b> , 75, 299-308	53
1531	Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. <b>2005</b> , 78, 265-74	71
1530	Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. <b>2005</b> , 84, 25-32	16
1529	Preliminary psychometric evaluation of the Child Health Ratings Inventory (CHRI) and Disease-Specific Impairment Inventory-Hematopoietic Stem Cell Transplantation (DSII-HSCT) in parents and children. <b>2005</b> , 14, 1613-25	56
1528	Associa�� dos n�veis de citocinas no p��-transplante de c�lulas-tronco hematopo�ticas com a Doen�� do Enxerto Contra o Hospedeiro aguda. <b>2005</b> , 27, 166	
1527	Late Gastrointestinal and Hepatic Effects. <b>2005</b> , 181-202	5
1526	Manifesta��es tegumentares da doen�� enxerto contra hospedeiro em pacientes transplantados de medula �ssea. <b>2005</b> , 80, 69-80	9
1525	Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease. <b>2005</b> , 46, 4519-27	42



1524	Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. <b>2005</b> , 25, 490-3	109
1523	Survivors of Childhood and Adolescent Cancer. <b>2005</b> ,	25
1522	Interleukin-1 polymorphisms and graft-vs-host disease. <b>2005</b> , 46, 517-23	14
1521	Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. <b>2005</b> , 172, 384-90	70
1520	Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. <b>2005</b> , 11, 7164s-7170s	38
1519	Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report. <b>2005</b> , 22, 597-608	2
1518	Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. <b>2005</b> , 113, 220-7	11
1517	[Musculoskeletal manifestations in allogeneic hematopoietic stem cell transplantation]. <b>2005</b> , 1, 112-5	0
1516	Graft-vs-host disease: nutrition therapy in a challenging condition. <b>2005</b> , 20, 440-50	17
1515	Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. <b>2005</b> , 53, 591-601	64
1514	Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. <b>2005</b> , 11, 47-55	106
1513	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. <b>2005</b> , 11, 122-8	30
1512	Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. <b>2005</b> , 11, 307-13	70
1511	Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. <b>2005</b> , 11, 764-72	61
1510	National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. <b>2005</b> , 11, 945-56	2749
1509	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Preface to the Series. <b>2005</b> , 11, 943-944	16
1508	Life-threatening graft-vs-host disease. <b>2005</b> , 23, 285-300	33
1507	The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. <b>2006</b> , 47, 599-602	27

1506	Salivary antioxidant capacity in graft versus host disease. <b>2006</b> , 24, 269-77	13
1505	Diagnosis and treatment of chronic graft-versus-host disease. <b>2006</b> , 43, 70-80	30
1504	Banking and transplantation of umbilical cord blood in Guangzhou, China. <b>2006</b> , 8, 488-97	22
1503	Chronic graft-versus-host disease: Pathogenesis and clinical management. <b>2006</b> , 66, 1041-57	59
1502	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. <b>2006</b> , 107, 3065-73	412
1501	Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. <b>2006</b> , 12, 84-94	44
1500	Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <b>2006</b> , 12, 31-47	357
1499	Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. <b>2006</b> , 12, 126-37	127
1498	Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. <b>2006</b> , 12, 560-5	287
1497	Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. <b>2006</b> , 12, 719-28	30
1496	Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. <b>2006</b> , 12, 749-57	24
1495	The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. <b>2006</b> , 12, 876-84	215
1494	Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. <b>2006</b> , 12, 1073-84	106
1493	Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. <b>2006</b> , 12, 1150-60	60
1492	The changing face of graft-versus-host disease. <b>2006</b> , 25, 190-200	36
1491	Pre-transplant Disease Status is Important for an Improved Outcome of the Second Stem Cell Transplantation in the Myeloma Patients Receiving the First Autologous Stem Cell Transplantation. <b>2006</b> , 41, 36	1
1490	Inverse Tendency between Ex Vivo Expansion Potential of Hematopoietic Progenitors and Time to Engraftment after Hematopoietic Stem Cell Transplantation. <b>2006</b> , 26, 385-92	
1489	Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. <b>2006</b> , 108, 382-9	66

1488	Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. <b>2006</b> , 107, 2200-7	33
1487	Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. <b>2006</b> , 107, 2294-302	268
1486	Non-HLA gene polymorphisms and the outcome of allogeneic hemato-poietic stem cell transplantation. <b>2006</b> , 1, 239-53	8
1485	Chronic graft-versus-host disease. <b>2006</b> , 18, 126-31	35
1484	Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. <b>2006</b> , 82, 913-9	45
1483	Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. <b>2006</b> , 25, 674-8	33
1482	Chronic graft versus host disease. <b>2006</b> , 13, 426-35	93
1481	Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation. <b>2006</b> , 47, 594-606	43
1480	Hematopoietic stem cell transplantation for Diamond-Blackfan anemia: a report from the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology. <b>2007</b> , 11, 601-7	38
1479	Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. <b>2006</b> , 135, 524-32	87
1478	Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience. <b>2006</b> , 28, 189-97	7
1477	Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. <b>2006</b> , 37, 33-40	40
1476	Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. <b>2006</b> , 37, 135-41	11
1475	Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. <b>2006</b> , 37, 101-8	32
1474	Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation. <b>2006</b> , 37, 199-206	8
1473	Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. <b>2006</b> , 37, 57-64	16
1472	Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. <b>2006</b> , 37, 155-63	66
1471	Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. <b>2006</b> , 37, 289-96	24

1470	Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse. <b>2006</b> , 37, 493-8	16
1469	Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. <b>2006</b> , 37, 693-8	48
1468	Rapid helper T-cell recovery above $200 \times 10^6/l$ at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. <b>2006</b> , 37, 1119-28	95
1467	Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. <b>2006</b> , 37, 1129-34	52
1466	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <b>2006</b> , 37, 1135-41	83
1465	Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. <b>2006</b> , 38, 149-56	54
1464	Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. <b>2006</b> , 38, 377-84	56
1463	Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. <b>2006</b> , 38, 645-51	75
1462	Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin. <b>2006</b> , 38, 745-50	12
1461	Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. <b>2006</b> , 20, 707-14	49
1460	Chronic graft-versus-host disease. <b>2006</b> , 20, 15-27	104
1459	Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. <b>2006</b> , 83, 80-5	36
1458	Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. <b>2006</b> , 38, 17-21	78
1457	Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. <b>2006</b> , 76, 414-9	24
1456	The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. <b>2006</b> , 34, 389-96	121
1455	Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients. <b>2006</b> , 34, 1753-8	3
1454	Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy. <b>2006</b> , 21, 181-7	32
1453	Intramuscular deferoxamine in hereditary hemochromatosis. <b>2006</b> , 81, 225-6	3

1452	RhD alloimmunization without apparent exposure to RhD antigen. <b>2006</b> , 81, 218	2
1451	GVHD and prognostic factors. <b>2006</b> , 81, 221-2	
1450	Acute tumor lysis syndrome secondary to hydroxycarbamide in chronic myelomonocytic leukemia. <b>2006</b> , 81, 220-1	4
1449	Is the group of older sickle cell disease patients from Trinidad and Tobago different?. <b>2006</b> , 81, 219-20	3
1448	Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. <b>2006</b> , 81, 218-9	18
1447	23-bp endothelial protein C receptor (EPCR) gene insertion mutation in cancer patients with and without thrombosis. <b>2006</b> , 81, 220	4
1446	Exacerbation of chronic epidural abscess following a fludarabine-based preparative regimen. <b>2006</b> , 81, 222-4	2
1445	Severe thrombotic thrombocytopenic purpura (TTP) induced or exacerbated by the immunostimulatory herb Echinacea. <b>2006</b> , 81, 224	5
1444	Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia. <b>2006</b> , 81, 224-5	2
1443	Care for patients undergoing extracorporeal photopheresis to treat chronic graft-versus-host disease: review of the evidence. <b>2006</b> , 10, 795-802	6
1442	Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma. <b>2006</b> , 36, 432-8	6
1441	Pediatric Hematopoietic Stem Cell Transplantation. <b>2006</b> ,	1
1440	Maternal perspectives on children's health-related quality of life during the first year after pediatric hematopoietic stem cell transplant. <b>2006</b> , 31, 1100-15	60
1439	The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. <b>2007</b> , 13, 2916-22	74
1438	Spontaneous lacrimal punctal occlusion associated with ocular chronic graft-versus-host disease. <b>2007</b> , 32, 837-42	22
1437	Role of heat shock protein 47, a collagen-binding chaperone, in lacrimal gland pathology in patients with cGVHD. <b>2007</b> , 48, 1079-86	31
1436	Haematopoietic stem cell transplantation: can our genes predict clinical outcome?. <b>2007</b> , 9, 1-19	33
1435	Chimerism in systemic lupus erythematosus--three hypotheses. <b>2007</b> , 46, 200-8	19

1434	The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <b>2007</b> , 109, 1782-9	108
1433	Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. <b>2007</b> , 109, 1756-64	117
1432	Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. <b>2007</b> , 110, 237-41	190
1431	T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. <b>2007</b> , 110, 4552-9	95
1430	A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTTC) study. <b>2007</b> , 110, 4584-7	43
1429	Telemetric monitoring of pulmonary function after allogeneic hematopoietic stem cell transplantation. <b>2007</b> , 83, 554-60	17
1428	Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. <b>2007</b> , 29, 529-34	43
1427	Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. <b>2007</b> , 29, 678-87	44
1426	Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. <b>2007</b> , 84, 917-25	29
1425	Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. <b>2007</b> , 12, 193-7	8
1424	Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. <b>2007</b> , 39, 1615-9	8
1423	Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. <b>2007</b> , 39, 1710-3	83
1422	Prediction of nonrelapse mortality for patients surviving 100 days after allogeneic hematopoietic stem cell transplantation. <b>2007</b> , 39, 3375-9	6
1421	Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. <b>2007</b> , 13, 90-9	51
1420	A single-center pilot validation study of a new chronic GVHD skin scoring system. <b>2007</b> , 13, 715-23	38
1419	Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. <b>2007</b> , 13, 724-33	13
1418	Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. <b>2007</b> , 13, 844-52	59
1417	Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide. <b>2007</b> , 13, 863-70	14

1416	Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. <b>2007</b> , 13, 942-7	20
1415	Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). <b>2007</b> , 13, 1145-52	54
1414	High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. <b>2007</b> , 13, 1192-200	54
1413	Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. <b>2007</b> , 13, 1207-15	87
1412	Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. <b>2007</b> , 13, 1233-43	52
1411	Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. <b>2007</b> , 13, 1304-12	47
1410	Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. <b>2007</b> , 13, 1338-45	34
1409	CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. <b>2007</b> , 13, 1515-24	32
1408	Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. <b>2007</b> , 109, 1322-30	239
1407	Liver Immunology. <b>2007</b> ,	4
1406	Prednisone plus a calcineurin inhibitor are considered standard treatment for chronic graft-versus-host disease, but the best regimen for salvage treatment is not clear. <b>2007</b> , 23, 7-10	
1405	Scleroderma lung: pathogenesis, evaluation and current therapy. <b>2007</b> , 67, 985-96	11
1404	Ocular manifestations of chronic graft-versus-host disease in patients treated with extracorporeal photochemotherapy. <b>2007</b> , 17, 961-9	8
1403	Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. <b>2007</b> , 82, 45-52	130
1402	The effect of budesonide mouthwash on oral chronic graft versus host disease. <b>2007</b> , 82, 349-56	33
1401	Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism. <b>2007</b> , 82, 419-26	12
1400	Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. <b>2007</b> , 82, 873-80	13
1399	Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. <b>2007</b> , 82, 863-6	17



1398	Relationship of pretransplant hepatobiliary disease to bile duct damage occurring in the liver allograft. <b>1983</b> , 3, 84-9	40
1397	Second solid cancers after allogeneic hematopoietic stem cell transplantation. <b>2007</b> , 109, 84-92	69
1396	Bone health in children and adolescents after allogeneic stem cell transplantation: high prevalence of vertebral compression fractures. <b>2007</b> , 110, 442-51	20
1395	Do maternal cells trigger or perpetuate autoimmune diseases in children?. <b>2007</b> , 5, 9	12
1394	Hepatic pattern of graft versus host disease in children. <b>2007</b> , 49, 727-30	21
1393	T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. <b>2008</b> , 30, 499-507	4
1392	A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. <b>2007</b> , 39, 179-88	22
1391	Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. <b>2007</b> , 39, 217-21	11
1390	Experience of severe fatigue in long-term survivors of stem cell transplantation. <b>2007</b> , 39, 595-603	78
1389	Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. <b>2007</b> , 39, 555-61	79
1388	New clinical grading system for chronic GVHD predicts duration of systemic immunosuppressive treatment and GVHD-specific and overall survival. <b>2007</b> , 39, 711-6	2
1387	Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. <b>2007</b> , 40, 29-35	48
1386	Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. <b>2007</b> , 40, 137-43	13
1385	Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. <b>2007</b> , 40, 225-33	166
1384	Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation. <b>2007</b> , 40, 193-200	38
1383	HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. <b>2007</b> , 40, 319-27	11
1382	Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. <b>2007</b> , 40, 209-17	48
1381	Infliximab for GVHD therapy in children. <b>2007</b> , 40, 473-80	39



1380	Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. <b>2007</b> , 40, 585-92	13
1379	Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. <b>2007</b> , 40, 683-9	16
1378	Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD. <b>2007</b> , 40, 779-84	6
1377	Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. <b>2007</b> , 40, 965-71	40
1376	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. <b>2007</b> , 21, 129-35	43
1375	Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <b>2007</b> , 21, 472-9	45
1374	Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. <b>2007</b> , 50 Suppl 1, 24-37	19
1373	Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. <b>2007</b> , 9, 189-95	75
1372	Histopathology of graft versus host disease of the liver. <b>2007</b> , 50, 727-38	42
1371	Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. <b>2007</b> , 137, 142-51	49
1370	Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. <b>2007</b> , 138, 101-9	42
1369	The management and outcome of chronic graft-versus-host disease. <b>2007</b> , 138, 131-45	31
1368	Disease of the liver following bone marrow transplantation in children: incidence, clinical course and outcome in a long-term perspective. <b>2007</b> , 87, 579-583	18
1367	Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning. <b>2007</b> , 78, 314-21	42
1366	FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. <b>2007</b> , 85, 154-62	26
1365	Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. <b>2007</b> , 85, 246-55	9
1364	The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. <b>2007</b> , 85, 446-55	6
1363	High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. <b>2007</b> , 110, 4576-83	957

1362	Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes. <b>2008</b> , 41, 56-78	22
1361	Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. <b>2008</b> , 87, 167-171	7
1360	Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease. <b>2008</b> , 88, 575-582	7
1359	Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. <b>2008</b> , 113, 3315-22	88
1358	The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. <b>2008</b> , 83, 784-8	10
1357	Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. <b>2008</b> , 87, 382-386	0
1356	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. <b>2008</b> , 112, 3574-81	242
1355	Oral graft-versus-host disease. <b>2008</b> , 14, 396-412	89
1354	Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. <b>2008</b> , 42, 541-6	12
1353	Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies. <b>2008</b> , 42, 51-6	25
1352	Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. <b>2008</b> , 42, 83-91	45
1351	Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. <b>2008</b> , 41, 55-62	71
1350	Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. <b>2008</b> , 41, 267-73	39
1349	Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. <b>2008</b> , 41, 293-302	83
1348	Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. <b>2008</b> , 41, 571-7	27
1347	A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. <b>2008</b> , 41, 805-12	37
1346	Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. <b>2008</b> , 41, 779-84	38
1345	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. <b>2008</b> , 41, 887-93	17

1344	Microchimerism decades after transfusion among combat-injured US veterans from the Vietnam, Korean, and World War II conflicts. <b>2008</b> , 48, 1609-15	35
1343	Allogeneic stem cell transplantation in children with leukemia using human leukocyte antigen-mismatched unrelated donors. <b>2008</b> , 12, 24-31	6
1342	Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. <b>2008</b> , 10, 252-9	20
1341	Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. <b>1992</b> , 88, 512-9	42
1340	Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE). <b>1993</b> , 94, 127-33	14
1339	High levels of anti-cytoskeleton autoantibodies are frequently associated with chronic GVHD. <b>2008</b> , 67, 301-305	
1338	Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. <b>1993</b> , 85, 558-65	62
1337	Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. <b>2008</b> , 36, 1-8	56
1336	Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. <b>2008</b> , 36, 1047-54	39
1335	Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan. <b>2008</b> , 80, 251-7	19
1334	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. <b>2008</b> , 80, 419-28	16
1333	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. <b>1984</b> , 4, 105-16	97
1332	Histological changes of the liver in experimental graft-versus-host disease across minor histocompatibility barriers. VIII. Role of eosinophil infiltration. <b>1996</b> , 16, 42-7	10
1331	Vascular endothelium as 'novel' target of graft-versus-host disease. <b>2008</b> , 21, 139-48	91
1330	Vascular endothelium and graft-versus-host disease. <b>2008</b> , 21, 129-38	64
1329	Diagnosis and manifestations of chronic graft-versus-host disease. <b>2008</b> , 21, 251-7	81
1328	Impact of graft-versus-host disease on survival. <b>2008</b> , 21, 193-204	43
1327	Stem Cells and their Potential for Clinical Application. <b>2008</b> ,	2

1326	Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. <b>2008</b> , 40, 3637-42	9
1325	Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. <b>2008</b> , 14, 197-207	82
1324	Murine models of chronic graft-versus-host disease: insights and unresolved issues. <b>2008</b> , 14, 365-78	110
1323	Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. <b>2008</b> , 14, 268-81	4
1322	Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease. <b>2008</b> , 14, 426-37	11
1321	Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. <b>2008</b> , 14, 458-68	56
1320	Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. <b>2008</b> , 14, 651-7	17
1319	Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. <b>2008</b> , 14, 831-9	98
1318	Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. <b>2008</b> , 14, 913-9	55
1317	Unrelated cord blood transplantation for severe aplastic anemia. <b>2008</b> , 14, 1057-1063	83
1316	Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. <b>2008</b> , 14, 1163-1171	72
1315	Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). <b>2008</b> , 14, 1217-25	109
1314	Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. <b>2008</b> , 14, 1341-7	49
1313	Diffusion capacity predicts long-term survival after allogeneic bone marrow transplantation for acute lymphoblastic leukemia. <b>2008</b> , 71, 234-40	5
1312	Advances in pediatric hematopoietic stem cell transplantation. <b>2008</b> , 7, 1533-9	24
1311	Cutaneous graft-versus-host disease: a guide for the dermatologist. <b>2008</b> , 216, 287-304	81
1310	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. <b>2008</b> , 93, 257-64	117
1309	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. <b>2008</b> , 49, 1494-500	2

1308	Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. <b>2008</b> , 112, 4318-27	253
1307	Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. <b>2008</b> , 112, 415-25	77
1306	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. <b>2008</b> , 112, 990-8	256
1305	Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. <b>2008</b> , 112, 2163-6	20
1304	Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. <b>2008</b> , 111, 2462-9	41
1303	Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over. <b>2008</b> , 47, 379-83	5
1302	Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. <b>2008</b> , 93, 1203-10	129
1301	Chronic graft-versus-host disease. <b>2008</b> , 14, 1974-86	11
1300	Efficacy and early complications of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation. <b>2008</b> , 1, 189-92	1
1299	Non-pharmacologic strategies in hematopoietic stem cell transplantation. <b>2008</b> , 14, 1987-96	2
1298	Current and future approaches for control of graft-versus-host disease. <b>2008</b> , 1, 111	23
1297	The involvement of the liver in systemic diseases. <b>2008</b> , 42, 69-80	34
1296	High-resolution CT findings of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <b>2008</b> , 23, 244-50	58
1295	Papel das citocinas na imunopatogênese da doença do enxerto contra o hospedeiro. <b>2008</b> , 30,	1
1294	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. <b>2008</b> , 93, 1343-50	15
1293	Long-term Evaluation After Topical Cyclosporine Treatment in Dry Eye Patients With Graft-Versus-Host Disease. <b>2009</b> , 50, 27	2
1292	Clinical utility of rituximab in chronic graft-versus-host disease. <b>2009</b> , 43, 316-21	22
1291	Maladie du greffon contre l'hôte. <b>2009</b> , 113-122	

1290	Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. <b>2009</b> , 49, 1851-60	83
1289	Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. <b>2009</b> , 15, 4759-68	36
1288	Multiple morphea-like lesions associated with chronic graft-versus-host disease after cord blood transplantation. <b>2009</b> , 89, 86-7	5
1287	Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. <b>2009</b> , 15, 4777-83	86
1286	Chronic graft-versus-host disease. <b>2009</b> , 401-407	4
1285	Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. <b>2009</b> , 27, e147-9	45
1284	Adenovirus DNA positivity in nasopharyngeal aspirate preceding hematopoietic stem cell transplantation: a very strong risk factor for adenovirus DNAemia in pediatric patients. <b>2009</b> , 49, 1536-9	25
1283	Cyclosporin A pretreatment of both donor and recipient undergoing allogeneic bone marrow transplantation. <b>1985</b> , 35, 386-93	1
1282	Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. <b>1986</b> , 36, 499-506	29
1281	Graft-versus-leukaemia activity associated with cytomegalovirus seropositive bone marrow donors but separated from graft-versus-host disease in allograft recipients with AML. <b>1987</b> , 38, 350-5	5
1280	Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. <b>2009</b> , 40, 643-7	15
1279	Therapeutic experience on multiple contractures in sclerodermoid chronic graft versus host disease. <b>2009</b> , 17, 851-5	8
1278	Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. <b>2009</b> , 29, 696-704	19
1277	Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients. <b>2009</b> , 89, 98-105	4
1276	Polymyositis and myocarditis after donor lymphocyte infusion. <b>2009</b> , 90, 113-116	12
1275	Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. <b>2009</b> , 90, 253-260	43
1274	Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age. <b>2009</b> , 88, 581-8	6
1273	High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. <b>2009</b> , 88, 1015-24	15

1272	The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. <b>2009</b> , 53, 1100-6	18
1271	Oral carcinoma after hematopoietic stem cell transplantation--a new classification based on a literature review over 30 years. <b>2009</b> , 1, 29	40
1270	Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. <b>2009</b> , 145, 107-14	22
1269	Feasibility of NIH consensus criteria for chronic graft-versus-host disease. <b>2009</b> , 23, 78-84	91
1268	The NIH consensus criteria for chronic graft-versus-host disease: far more than just another classification. <b>2009</b> , 23, 1-2	7
1267	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. <b>2009</b> , 23, 492-500	202
1266	The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. <b>2009</b> , 43, 29-36	45
1265	New classification of chronic GVHD: added clarity from the consensus diagnoses. <b>2009</b> , 43, 149-53	78
1264	Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group. <b>2009</b> , 43, 207-15	13
1263	Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. <b>2009</b> , 43, 469-76	29
1262	Unrelated cord blood transplantation after myeloablative conditioning in adults with ALL. <b>2009</b> , 43, 455-9	20
1261	Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. <b>2009</b> , 43, 477-80	10
1260	Patient socioeconomic status as a prognostic factor for allo-SCT. <b>2009</b> , 43, 571-7	24
1259	Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study. <b>2009</b> , 43, 611-7	10
1258	Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. <b>2009</b> , 43, 709-15	28
1257	Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. <b>2009</b> , 43, 717-23	41
1256	Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. <b>2009</b> , 44, 303-8	42
1255	Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. <b>2009</b> , 44, 333-8	18



1254	Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT. <b>2009</b> , 44, 589-94	8
1253	Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. <b>2009</b> , 44, 729-37	40
1252	Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies. <b>2009</b> , 13, 737-45	12
1251	Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. <b>2009</b> , 11, 413-23	40
1250	Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 31, 161-8	7
1249	B cells and transplantation: an educational resource. <b>2009</b> , 15, 104-13	17
1248	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. <b>2009</b> , 15, 101-8	45
1247	IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. <b>2009</b> , 15, 205-13	18
1246	First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. <b>2009</b> , 15, 505-11	19
1245	HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. <b>2009</b> , 15, 454-62	34
1244	Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. <b>2009</b> , 15, 471-82	20
1243	Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. <b>2009</b> , 15, 554-63	31
1242	Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. <b>2009</b> , 15, 618-25	94
1241	Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. <b>2009</b> , 15, 632-8	51
1240	Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. <b>2009</b> , 15, 730-40	45
1239	Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. <b>2009</b> , 15, 856-63	45
1238	Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. <b>2009</b> , 15, 864-71	50
1237	Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. <b>2009</b> , 15, 919-29	33



1236	HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States. <b>2009</b> , 15, 971-81	25
1235	Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. <b>2009</b> , 15, 1049-59	112
1234	Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). <b>2009</b> , 15, 1288-95	55
1233	Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. <b>2009</b> , 15, 1422-30	79
1232	A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of deescalation. <b>2009</b> , 15, 1563-70	36
1231	Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. <b>2009</b> , 15, 1603-8	19
1230	HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. <b>2009</b> , 43, 98-104	38
1229	Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease. <b>2009</b> , 41, 209-16	8
1228	Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors. <b>2009</b> , 50, 612-8	4
1227	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. <b>2009</b> , 10, 489-500	400
1226	Influence of lymphocyte recovery on outcome of haploidentical transplantation for hematologic malignancies. <b>2009</b> , 88, 322-330	20
1225	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <b>2009</b> , 113, 3110-8	136
1224	Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. <b>2009</b> , 113, 1834-40	55
1223	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <b>2009</b> , 113, 3865-74	236
1222	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <b>2009</b> , 114, 702-8	187
1221	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <b>2009</b> , 114, 5264-70	309
1220	NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. <b>2009</b> , 94, 1427-34	44
1219	Historical Aspects of Chronic Graft versus Host Disease. 3-7	

1218	Pathophysiology of Chronic Graft versus Host Disease. 17-30	6
1217	Incidence and Trends. 46-55	1
1216	Clinical Manifestations and Natural History. 56-69	4
1215	Animal Models of Chronic Graft versus Host Disease. 31-45	1
1214	Risk Factors and Predictive Models for Chronic Graft versus Host Disease. 70-78	
1213	Diagnosis and Staging. 87-100	2
1212	Front Line Treatment of Chronic Graft versus Host Disease. 124-133	6
1211	Gastrointestinal and Hepatic Manifestations of Chronic Graft versus Host Disease. 216-228	4
1210	Infections. 268-288	1
1209	Other Manifestations of Chronic Graft versus Host Disease. 302-313	
1208	A retrospective comparison of allogeneic peripheral blood stem cell versus bone marrow transplantation. <b>2009</b> , 2, 272-7	5
1207	Current insights into ocular graft-versus-host disease. <b>2010</b> , 21, 485-94	55
1206	Allogreffe de cellules souches h�matopo�iques: r�alisation et complications. <b>2010</b> , 5, 1-19	
1205	Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation. <b>2010</b> , 89, 1354-61	17
1204	Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GVHD. <b>2010</b> , 32, 589-93	21
1203	Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. <b>2010</b> , 115, 2311-8	29
1202	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <b>2010</b> , 115, 3224-30	281
1201	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <b>2010</b> , 116, 4007-15	94

1200	Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. <b>2010</b> , 116, 1849-56	34
1199	Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors. <b>2010</b> , 89, 813-20	2
1198	Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. <b>2010</b> , 89, 1045-52	7
1197	Outcomes of matched sibling and alternative donor stem cell transplantation for 26 children with severe aplastic anemia. <b>2010</b> , 91, 54-60	8
1196	Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. <b>2010</b> , 91, 661-9	19
1195	Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry. <b>2010</b> , 91, 855-64	34
1194	The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status. <b>2010</b> , 136, 302-6	33
1193	Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience. <b>2010</b> , 127, 1446-52	7
1192	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. <b>2010</b> , 85, 290-3	1
1191	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. <b>2010</b> , 85, 288-90	50
1190	Is the JAK2(V617F) mutation detectable in healthy volunteers?. <b>2010</b> , 85, 287-8	28
1189	Detection of hereditary hemochromatosis and biochemical iron overload in primary care: a multicenter case finding study in Spain. <b>2010</b> , 85, 294-6	4
1188	Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. <b>2010</b> , 85, 296-9	
1187	Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions. <b>2010</b> , 85, 300-1	1
1186	ASH 2009 meeting report—Top 10 clinically oriented abstracts in acute leukemia. <b>2010</b> , 85, 277-280	0
1185	ASH 2009 meeting report—Top 10 clinically oriented abstracts in lymphoma. <b>2010</b> , 85, 280-283	
1184	ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic myeloid leukemia. <b>2010</b> , 85, 283-286	0
1183	Non-neoplastic diseases of the intra- and extrahepatic bile ducts. <b>2010</b> , 16, 380-387	

1182	Outcome of Chinese children with unrelated donor hematopoietic stem cell transplantation. <b>2010</b> , 55, 1386-92	3
1181	Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant. <b>2010</b> , 50, 501-6	15
1180	Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. <b>2010</b> , 50, 1359-69	84
1179	Basement membrane antibodies in sera of haematopoietic cell recipients are associated with graft-versus-host disease. <b>2010</b> , 24, 587-94	11
1178	Early-onset lichenoid graft-vs.-host disease: a unique variant of acute graft-vs.-host disease occurring in peripheral blood stem cell transplant recipients. <b>2010</b> , 37, 549-58	1
1177	Clinicopathologic characteristics of cutaneous chronic graft-versus-host diseases: a retrospective study in Korean patients. <b>2010</b> , 49, 1386-92	20
1176	Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. <b>2010</b> , 148, 323-31	52
1175	Optimal management of chronic graft-versus-host disease in children. <b>2010</b> , 150, 278-92	29
1174	The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. <b>2010</b> , 24, 1852-8	49
1173	Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. <b>2010</b> , 24, 1236-9	22
1172	Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. <b>2010</b> , 45, 295-302	56
1171	Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. <b>2010</b> , 45, 558-64	48
1170	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. <b>2010</b> , 45, 450-7	29
1169	Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. <b>2010</b> , 45, 1732-40	186
1168	Myeloablative hematopoietic stem cell transplantation for myelodysplastic syndrome in patients younger than 55 years: impact of comorbidity and disease burden on the long-term outcome. <b>2010</b> , 32, 222-9	18
1167	Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita. <b>2011</b> , 15, 161-6	26
1166	Transplante de células-tronco hematopoiéticas em crianças e adolescentes com leucemia aguda: experiência de duas instituições Brasileiras. <b>2010</b> , 32, 350-357	1
1165	Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. <b>2010</b> , 28, 3344-51	62

1164	T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. <b>2010</b> , 28, 3695-700	124
1163	Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobin. <b>2010</b> , 42, 651-61	10
1162	Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. <b>2010</b> , 28, 3730-8	312
1161	Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. <b>2010</b> , 45, 1068-76	30
1160	Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset. <b>2010</b> , 45, 1540-5	11
1159	CsA exposure is associated with acute GVHD and relapse in children after SCT. <b>2010</b> , 45, 1056-61	20
1158	HLA-matched sibling transplantation with BM and CD34(+)-purified PBSCs in adult patients with high-risk severe aplastic anemia to overcome graft rejection without an increase in GVHD. <b>2010</b> , 45, 1497-501	12
1157	The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. <b>2010</b> , 45, 985-92	27
1156	Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. <b>2010</b> , 45, 1508-13	41
1155	Pathogenesis and management of graft-versus-host disease. <b>2010</b> , 30, 75-101	128
1154	Chronic graft-versus-host disease (GVHD) in children. <b>2010</b> , 57, 297-322	87
1153	Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. <b>2010</b> , 45, 1204-11	68
1152	Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. <b>2010</b> , 16, 86-94	74
1151	Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. <b>2010</b> , 16, 320-32	20
1150	Current challenges in chronic graft-versus-host disease. <b>2010</b> , 16, S146-51	34
1149	Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. <b>2010</b> , 16, 482-9	207
1148	Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. <b>2010</b> , 16, 967-75	36
1147	Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. <b>2010</b> , 16, 1428-35	55

1146	Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. <b>2010</b> , 16, 1442-50	53
1145	Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. <b>2010</b> , 16, 1589-95	28
1144	Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. <b>2010</b> , 16, 1728-37	20
1143	The impact of immunogenetics and clinical factors on the outcome of unrelated cord blood transplantation: the Milano Cord Blood Bank data. <b>2010</b> , 42, 283-8	1
1142	Clinical update on graft-versus-host disease in children. <b>2010</b> , 29, 92-105	16
1141	Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. <b>2010</b> , 45, 1174-80	17
1140	Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. <b>2010</b> , 115, 3437-46	139
1139	Graft-Versus-Host Disease. <b>2011</b> , 178.1-178.12	
1138	A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT. <b>2011</b> , 46, 1455-63	20
1137	Childhood Leukemia. <b>2011</b> ,	6
1136	Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. <b>2011</b> , 53, 376-83	12
1135	Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors. <b>2011</b> , 17, 93-100	2
1134	The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia. <b>2011</b> , 17, 101-8	23
1133	Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. <b>2011</b> , 17, 167-75	45
1132	One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. <b>2011</b> , 17, 640-8	44
1131	Limbus damage in ocular graft-versus-host disease. <b>2011</b> , 17, 270-3	24
1130	Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. <b>2011</b> , 17, 717-22	18
1129	Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. <b>2011</b> , 17, 821-30	115

1128	Prolonged thrombocytopenia following allogeneic hematopoietic stem cell transplantation and its association with a reduction in ploidy and an immaturation of megakaryocytes. <b>2011</b> , 17, 274-80	33
1127	Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. <b>2011</b> , 17, 861-6	38
1126	Prophylaxis with sirolimus and tacrolimus + antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. <b>2011</b> , 17, 916-22	25
1125	The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age. <b>2011</b> , 17, 1205-13	5
1124	A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. <b>2011</b> , 17, 1308-15	15
1123	Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. <b>2011</b> , 17, 1093-7	10
1122	Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. <b>2011</b> , 17, 1673-8	24
1121	Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. <b>2011</b> , 17, 1114-20	50
1120	Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. <b>2011</b> , 17, 1833-40	12
1119	Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. <b>2011</b> , 17, 1796-803	108
1118	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <b>2011</b> , 117, 6714-20	105
1117	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <b>2011</b> , 117, 3214-9	420
1116	Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. <b>2011</b> , 118, 4250-7	71
1115	Influence of glutathione S-transferase T1 donor/recipient mismatch and anti-GSTT1 antibodies in hepatic graft-versus-host-disease. <b>2011</b> , 141, 140-4	6
1114	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. <b>2011</b> , 42, 254-68	14
1113	Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome. <b>2011</b> , 23, 50-7	11
1112	Extracorporeal photochemotherapy induces arginase 1 in patients with graft versus host disease. <b>2011</b> , 24, 100-6	17
1111	Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts. <b>2011</b> , 28, 552-8	13



1110	Treatment of chronic graft-versus-host disease: Past, present and future. <b>2011</b> , 46, 153-63	65
1109	Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host disease. <b>2011</b> , 52, 779-86	6
1108	Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies. <b>2011</b> , 6, e23827	12
1107	A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. <b>2011</b> , 6, e26229	149
1106	Visual acuity and anterior segment findings in chronic graft-versus-host disease. <b>2011</b> , 30, 1392-7	25
1105	Higher doses of CD34+ PBPC are associated with a rapid acquisition of full donor chimerism and lower risk of relapse after allogeneic transplantation in pediatric patients with hematological malignancies. <b>2011</b> , 33, 185-9	5
1104	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. <b>2011</b> , 117, 6375-82	232
1103	A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRα antibodies. <b>2011</b> , 118, 4070-8	36
1102	How I conduct a comprehensive chronic graft-versus-host disease assessment. <b>2011</b> , 118, 2679-87	33
1101	Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. <b>2011</b> , 118, 4472-9	41
1100	Chronic GVHD: a new risk score?. <b>2011</b> , 117, 6408-9	4
1099	Graft-vs-host disease following allogeneic hematopoietic cell transplantation. <b>2011</b> , 18, 268-76	42
1098	Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. <b>2011</b> , 4, 149-56	8
1097	Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. <b>2011</b> , 25, 468-74	27
1096	Clinical features of late onset non-infectious pulmonary complications following pediatric allogeneic hematopoietic stem cell transplantation. <b>2011</b> , 25, E168-76	13
1095	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci�t� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <b>2011</b> , 152, 331-9	85
1094	Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. <b>2011</b> , 25, 75-81	39
1093	Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. <b>2011</b> , 25, 449-54	37



1092	Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia. <b>2011</b> , 25, 1548-54	16
1091	Evaluation of schistocyte monitoring after haematopoietic stem cell transplantation. <b>2011</b> , 33, 343-56	8
1090	Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia. <b>2011</b> , 87, 172-81	5
1089	Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients. <b>2011</b> , 87, 531-8	9
1088	Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. <b>2011</b> , 87, 521-30	10
1087	Dry eye disease in chronic graft-versus-host disease: results from a Spanish retrospective cohort study. <b>2011</b> , 43, 1934-8	12
1086	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <b>2011</b> , 118, 4242-9	169
1085	Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease. <b>2011</b> , 15, 179-83	5
1084	Mortality and medical morbidity beyond 2 years after allogeneic hematopoietic stem cell transplantation: experience at a single institution. <b>2011</b> , 93, 517-522	14
1083	Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. <b>2011</b> , 93, 532-541	11
1082	Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. <b>2011</b> , 94, 193-202	20
1081	Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant. <b>2011</b> , 94, 266-278	2
1080	Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. <b>2011</b> , 57, 660-5	18
1079	The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. <b>2011</b> , 57, 135-41	16
1078	Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. <b>2011</b> , 86, 203-5	86
1077	Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. <b>2011</b> , 86, 209-13	16
1076	In vivo T-cell depletion with pretransplant low-dose antithymocyte globulin is associated with reduced transplant-related mortality and improved clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation from unrelated and partially matched related donors. <b>2011</b> , 86, 214-7	8
1075	Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. <b>2011</b> , 86, 206-9	127

1074	Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. <b>2011</b> , 86, 217-20	171
1073	Evaluation of the free $\beta$ -hemoglobin pool in red blood cells: a new test providing a scale of $\beta$ -thalassemia severity. <b>2011</b> , 86, 199-202	10
1072	Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. <b>2011</b> , 86, 227-30	17
1071	High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma. <b>2011</b> , 86, 224-7	9
1070	Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?. <b>2011</b> , 86, 223-4	6
1069	Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. <b>2011</b> , 86, 220-3	27
1068	Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. <b>2011</b> , 86, 230-4	16
1067	The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis. <b>2011</b> , 29, 22-30	3
1066	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <b>2011</b> , 29, 202-10	12
1065	Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT. <b>2011</b> , 46, 1444-9	10
1064	Cord colitis syndrome in cord-blood stem-cell transplantation. <b>2011</b> , 365, 815-24	86
1063	Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. <b>2011</b> , 46, 192-9	8
1062	Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation. <b>2011</b> , 46, 993-9	7
1061	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. <b>2011</b> , 46, 557-61	18
1060	Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions. <b>2011</b> , 46, 319-21	5
1059	Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. <b>2011</b> , 46, 257-61	24
1058	Biomarkers in chronic graft-versus-host disease. <b>2011</b> , 4, 329-42	17
1057	Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. <b>2011</b> , 96, 1344-50	47

1056	Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. <b>2011</b> , 46, 1071-6	21
1055	Use of cryoprotectant-depleted allogeneic peripheral blood stem cells for transplantation. <b>2011</b> , 16, 221-4	4
1054	The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. <b>2011</b> , 96, 1678-84	56
1053	Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience. <b>2011</b> , 46, 244-9	6
1052	Air-leak syndrome following allo-SCT in adult patients: report from the Kanto Study Group for Cell Therapy in Japan. <b>2011</b> , 46, 379-84	26
1051	Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. <b>2011</b> , 46, 516-22	22
1050	GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. <b>2011</b> , 46, 668-75	18
1049	Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia. <b>2011</b> , 46, 1256-62	6
1048	Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. <b>2011</b> , 46, 1510-8	48
1047	A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. <b>2011</b> , 46, 238-43	13
1046	TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies. <b>2011</b> , 46, 1057-62	8
1045	Iron overload in allogeneic hematopoietic stem cell transplant recipients. <b>2012</b> , 136, 532-8	12
1044	Comparison of stem cell sources in the severity of dry eye after allogeneic haematopoietic stem cell transplantation. <b>2012</b> , 96, 34-7	33
1043	Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. <b>2012</b> , 47, 499-507	73
1042	Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. <b>2012</b> , 47, 1287-93	112
1041	The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. <b>2012</b> , 47, 639-45	59
1040	Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. <b>2012</b> , 47, 1564-8	9
1039	Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. <b>2012</b> , 47, 1470-3	65

1038	Future trends in hematopoietic stem cell transplantation. <b>2012</b> , 43, 165-70	4
1037	Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome. <b>2012</b> , 47, 669-76	18
1036	Peripheral-blood stem cells versus bone marrow from unrelated donors. <b>2012</b> , 367, 1487-96	620
1035	CT findings of late-onset noninfectious pulmonary complications in patients with pathologically proven graft-versus-host disease after allogeneic stem cell transplant. <b>2012</b> , 199, 581-7	29
1034	Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. <b>2012</b> , 53, 1525-9	22
1033	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. <b>2012</b> , 47, 831-7	28
1032	Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: a single center study of 190 recipients. <b>2012</b> , 44, 100-7	20
1031	Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. <b>2012</b> , 28, 479-83	60
1030	Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art. <b>2012</b> , 12, 1017-30	8
1029	Severe hypercholesterolemia in patients with graft-vs-host disease affecting the liver after stem cell transplantation. <b>2012</b> , 18, 90-7	8
1028	Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. <b>2012</b> , 26, 746-56	74
1027	Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. <b>2012</b> , 26, 2469-73	23
1026	Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia. <b>2012</b> , 97, 1014-9	7
1025	Clinical Results of Extracorporeal Photopheresis. <b>2012</b> , 39, 254-262	11
1024	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <b>2012</b> , 97, 1187-95	10
1023	Mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation. <b>2012</b> ,	
1022	The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience. <b>2012</b> , 34, 101-7	14
1021	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <b>2012</b> , 97, 451-8	62

1020	Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. <b>2012</b> , 119, 3908-16	192
1019	Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. <b>2012</b> , 120, 4246-55	53
1018	cGVHD of skin: simple tools, great advances. <b>2012</b> , 120, 2537-8	
1017	Keep up the heat on IL-1. <b>2012</b> , 120, 2538-9	10
1016	Toll-like receptor gene polymorphisms confer susceptibility to graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <b>2012</b> , 76, 336-41	19
1015	The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. <b>2012</b> , 64, 879-85	12
1014	Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. <b>2012</b> , 18, 1649-55	21
1013	Extensive dental caries in patients with oral chronic graft-versus-host disease. <b>2012</b> , 18, 1573-9	24
1012	HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. <b>2012</b> , 18, 1302-8	11
1011	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <b>2012</b> , 53, 96-102	17
1010	Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. <b>2012</b> , 119, 1892-8	56
1009	Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. <b>2012</b> , 47, 1442-7	19
1008	Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. <b>2012</b> , 47, 1474-8	29
1007	Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. <b>2012</b> , 47, 1171-7	34
1006	Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC. <b>2012</b> , 18, 250-6	4
1005	Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. <b>2012</b> , 18, 593-9	21
1004	Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. <b>2012</b> , 18, 698-707	16
1003	The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants. <b>2012</b> , 18, 722-30	9

1002	Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation. <b>2012</b> , 18, 739-46	27
1001	Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). <b>2012</b> , 18, 852-60	11
1000	Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients. <b>2012</b> , 18, 388-95	6
999	Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia. <b>2012</b> , 18, 894-902	11
998	Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. <b>2012</b> , CD009159	23
997	Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. <b>2012</b> , 49, 43-58	26
996	Miscellaneous Conditions. <b>2012</b> , 270-277	
995	Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia. <b>2012</b> , 127, 81-9	6
994	Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin. <b>2012</b> , 53, 162-5	
993	Miscellaneous Disorders of the Large Intestine. <b>2012</b> , 748-756	
992	Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. <b>2012</b> , 18, 1446-54	19
991	Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity. <b>2012</b> , 18, 1430-7	12
990	Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients. <b>2012</b> , 29, 461-71	17
989	Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease. <b>2012</b> , 7, e44416	7
988	Are we making progress in GVHD prophylaxis and treatment?. <b>2012</b> , 2012, 251-264	35
987	Transplantation pathology. <b>2012</b> , 853-933	5
986	The effectiveness of tacrolimus and minidose methotrexate in the prevention of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in children: a single-center study in Korea. <b>2012</b> , 47, 113-8	5
985	Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). <b>2012</b> , 59, 725-31	26

984	Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. <b>2012</b> , 87, 770-5	11
983	Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. <b>2012</b> , 87, 929-31	5
982	Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation. <b>2012</b> , 60, 225-33	13
981	Immune reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with HLA-identical sibling transplantation. <b>2012</b> , 32, 268-80	70
980	Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. <b>2012</b> , 91, 1305-12	30
979	Oral cGVHD screening tests in the diagnosis of systemic chronic graft-versus-host disease. <b>2012</b> , 16, 565-70	4
978	A single-center study of hematopoietic stem cell transplantation for primary immune deficiencies (PID). <b>2012</b> , 16, 63-72	11
977	Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. <b>2012</b> , 40, 431-5	3
976	Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and National Institutes of Health classifications. <b>2012</b> , 52, 2007-15	37
975	Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. <b>2012</b> , 88, 52-60	42
974	Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies. <b>2012</b> , 88, 39-45	23
973	Unrelated cord blood transplantation after myeloablative conditioning regimen in adolescent and young adult patients with hematologic malignancies: a single institute analysis. <b>2012</b> , 36, 128-31	2
972	Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. <b>2012</b> , 157, 339-46	85
971	Diagnosis and management of chronic graft-versus-host disease. <b>2012</b> , 158, 46-61	121
970	The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. <b>2012</b> , 26, 284-91	31
969	Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantation. <b>2012</b> , 26, 476-83	12
968	Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. <b>2012</b> , 87, 349-53	22
967	TLI in refractory chronic GVHD. <b>2013</b> , 48, 854-8	6



966	The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. <b>2013</b> , 146, 104-11	12
965	Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. <b>2013</b> , 92, 1397-403	15
964	Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. <b>2013</b> , 92, 1121-8	24
963	Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia. <b>2013</b> , 92, 249-54	5
962	Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. <b>2013</b> , 48, 901-7	19
961	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. <b>2013</b> , 119, 986-92	51
960	Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. <b>2013</b> , 19, 746-53	65
959	Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms. <b>2013</b> , 19, 1725-30	30
958	Time-related arterial changes after allogeneic hematopoietic stem cell transplantation in children. <b>2013</b> , 73, 777-82	5
957	Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. <b>2013</b> , 48, 1317-23	27
956	Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. <b>2013</b> , 48, 1040-5	38
955	Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. <b>2013</b> , 48, 1460-4	22
954	Outcomes of hematopoietic stem cell transplantation in primary immunodeficiency: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. <b>2013</b> , 19, 338-43	26
953	NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. <b>2013</b> , 24, 1363-70	27
952	Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. <b>2013</b> , 19, 934-9	20
951	Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. <b>2013</b> , 98, 463-71	3
950	Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. <b>2013</b> , 19, 1244-53	70
949	Minor histocompatibility antigens as determinants for graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. <b>2013</b> , 40, 495-501	11



948	Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia. <b>2013</b> , 37, 1477-81	20
947	The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. <b>2013</b> , 121, 4800-6	36
946	Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. <b>2013</b> , 41, 17-27	5
945	Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure After Hematopoietic Stem Cell Transplantation and Future Challenges. <b>2013</b> , 173-205	2
944	Parental emotional functioning declines with occurrence of clinical complications in pediatric hematopoietic stem cell transplant. <b>2013</b> , 21, 687-95	23
943	Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 19, 1465-73	80
942	Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. <b>2013</b> , 19, 1387-92	20
941	Ocular manifestations of graft-versus-host disease. <b>2013</b> , 27, 215-22	52
940	Providing personalized prognostic information for adult leukemia survivors. <b>2013</b> , 19, 1600-7	12
939	Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies. <b>2013</b> , 19, 486-91	18
938	Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden. <b>2013</b> , 19, 653-60	24
937	Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. <b>2013</b> , 19, 602-6	71
936	Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data. <b>2013</b> , 19, 576-83	1
935	Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies. <b>2013</b> , 19, 240-6	7
934	Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry. <b>2013</b> , 41, 924-33	24
933	Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. <b>2013</b> , 19, 735-40	21
932	Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. <b>2013</b> , 19, 298-304	71
931	Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. <b>2013</b> , 19, 625-31	68

930	Pre-engraftment syndrome after unrelated cord blood transplantation: a predictor of engraftment and acute graft-versus-host disease. <b>2013</b> , 19, 640-6	32
929	More than skin deep? Emerging therapies for chronic cutaneous GVHD. <b>2013</b> , 48, 323-37	17
928	Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. <b>2013</b> , 88, 477-84	24
927	Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT. <b>2013</b> , 48, 1104-11	17
926	Characteristics of chronic GVHD after cord blood transplantation. <b>2013</b> , 48, 1285-90	26
925	Kidney complications of hematopoietic stem cell transplantation. <b>2013</b> , 61, 809-21	35
924	Eosinophils in Human Disease. <b>2013</b> , 431-536	2
923	Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). <b>2013</b> , 90, 177-86	12
922	Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. <b>2013</b> , 19, 305-13	70
921	IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD. <b>2013</b> , 48, 722-8	20
920	Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. <b>2013</b> , 17, 582-8	23
919	Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease. <b>2013</b> , 97, 263-71	9
918	Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. <b>2013</b> , 122, 3651-8	69
917	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. <b>2013</b> , 98, 1273-81	25
916	The impact of morphological and immunohistological changes in minor salivary glands on the health of the oral cavity in HSCT patients. <b>2013</b> , 48, 1525-9	6
915	Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. <b>2013</b> , 48, 1098-103	15
914	Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. <b>2013</b> , 48, 249-52	14
913	Effects of spleen status on early outcomes after hematopoietic cell transplantation. <b>2013</b> , 48, 825-31	46

912	Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient. <b>2013</b> , 48, 144-5	1
911	RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 129, 137-45	5
910	Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. <b>2013</b> , 31, 1669-76	56
909	Peripheral blood stem cell transplantation from human leukocyte antigen-matched sibling donors and unrelated donors in acute myeloid leukemia patients. <b>2013</b> , 130, 206-16	5
908	Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group. <b>2013</b> , 162, 383-91	24
907	Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation. <b>2013</b> , 2013, 402980	31
906	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. <b>2013</b> , 2013, 414959	8
905	Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan. <b>2013</b> , 2013, 232519	3
904	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. <b>2013</b> , 27, E368-74	41
903	Polymorphism in the interleukin-7 receptor-alpha and outcome after allogeneic hematopoietic cell transplantation with matched unrelated donor. <b>2013</b> , 78, 214-20	18
902	Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. <b>2013</b> , 54, 2671-7	12
901	Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. <b>2013</b> , 27, E91-E100	14
900	A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. <b>2013</b> , 26, 631-9	18
899	Distinctive disease subgroups according to differentiation stages in adult patients with T-cell acute lymphoblastic leukemia. <b>2013</b> , 90, 301-7	3
898	Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. <b>2013</b> , 43, 838-50	16
897	The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series. <b>2013</b> , 54, 1020-7	3
896	Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?. <b>2013</b> , 5, 553-6	
895	International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). <b>2013</b> , 3, 3419	120

894	Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. <b>2013</b> , 121, 3981-7	154
893	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <b>2013</b> , 122, 1974-82	69
892	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. <b>2013</b> , 122, 3863-70	122
891	Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. <b>2013</b> , 121, 849-57	179
890	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. <b>2013</b> , 122, 4279-86	142
889	Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. <b>2013</b> , 121, 4603-10	112
888	Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. <b>2013</b> , 98, 437-43	46
887	PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA-matched sibling donor. <b>2013</b> , 60, 1513-9	10
886	De novo inflammatory bowel disease and its mimics after organ transplantation. <b>2013</b> , 19, 1518-27	24
885	Implication of early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation in children with leukemia. <b>2013</b> , 54, 62-70	6
884	Effect of Combined Treatment with Cyclosporine A and Cord Serum for Dry Eye Associated with Graft-Versus-Host-Disease. <b>2013</b> , 54, 587	1
883	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. <b>2014</b> , 49, 100-6	38
882	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. <b>2014</b> , 99, 1868-75	16
881	Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. <b>2014</b> , 2014, 282147	38
880	Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. <b>2014</b> , 49, 355-60	26
879	HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. <b>2014</b> , 49, 496-501	14
878	National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. <b>2014</b> , 55, 1106-12	21
877	Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children. <b>2014</b> , 49, 1521-7	15

876	A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. <b>2014</b> , 55, 2739-47	8
875	Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. <b>2014</b> , 55, 1274-80	3
874	The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. <b>2014</b> , 49, 55-61	32
873	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <b>2014</b> , 99, 378-84	14
872	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <b>2014</b> , 99, 1486-91	23
871	Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. <b>2014</b> , 55, 863-9	4
870	Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. <b>2014</b> , 28, 2235-40	69
869	Fludarabine Melphalan reduced-intensity conditioning allotransplantation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. <b>2014</b> , 49, 17-23	11
868	Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease. <b>2014</b> , 55, 1281-7	8
867	Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation. <b>2014</b> , 166, 749-57	22
866	Eosinophils in the blood of hematopoietic stem cell transplanted patients are activated and have different molecular marker profiles in acute and chronic graft-versus-host disease. <b>2014</b> , 2, 99-113	7
865	Safety and feasibility of granulocyte colony-stimulating factor (G-CSF) primed bone marrow (BM) using three days of G-CSF priming as stem cell source for pediatric allogeneic BM transplantation. <b>2014</b> , 18, 625-30	6
864	Graft-versus-host disease: why have we not made more progress?. <b>2014</b> , 21, 141-7	32
863	Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients. <b>2014</b> , 55, 1350-6	6
862	First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. <b>2014</b> , 99, 1784-91	66
861	The influence of interleukin-7 receptor $\beta$ -chain haplotypes on outcome after allogeneic hematopoietic cell transplantation. <b>2014</b> , 41, 521-7	2
860	Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning. <b>2014</b> , 20, 577-81	13
859	Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies. <b>2014</b> , 20, 742-7	5

858	Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning. <b>2014</b> , 20, 1150-5	11
857	Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. <b>2014</b> , 20, 1190-7	37
856	Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. <b>2014</b> , 20, 929-36	18
855	HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. <b>2014</b> , 20, 314-8	81
854	Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. <b>2014</b> , 20, 396-401	30
853	Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study. <b>2014</b> , 22, 295-305	8
852	Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia. <b>2014</b> , 164, 384-95	41
851	Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database. <b>2014</b> , 49, 767-72	2
850	Impact of sex incompatibility on the outcome of single-unit cord blood transplantation for adult patients with hematological malignancies. <b>2014</b> , 49, 634-9	7
849	Tc1 clonal T cell expansion during chronic graft-versus-host disease-associated hypereosinophilia. <b>2014</b> , 20, 739-42	1
848	A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases. <b>2014</b> , 20, 326-36	45
847	Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation. <b>2014</b> , 93, 645-51	13
846	Immune cell subset counts associated with graft-versus-host disease. <b>2014</b> , 20, 450-62	38
845	Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. <b>2014</b> , 42, 945-54	14
844	Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. <b>2014</b> , 58, 1700-6	25
843	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <b>2014</b> , 89, 83-7	20
842	Efficacy of prophylactic additional cranial irradiation and intrathecal chemotherapy for the prevention of CNS relapse after allogeneic hematopoietic SCT for childhood ALL. <b>2014</b> , 18, 518-23	3
841	Effect of CD8+ cell content on umbilical cord blood transplantation in adults with hematological malignancies. <b>2014</b> , 20, 1744-50	16



840	Haploidentical stem cell transplantation for acute leukemia patients who experienced early relapse within one year after the first transplantation. <b>2014</b> , 46, 3611-5	3
839	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. <b>2014</b> , CD010280	22
838	Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia. <b>2014</b> , 20, 1599-603	20
837	Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. <b>2014</b> , 20, 2023-8	18
836	Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. <b>2014</b> , 20, 1560-5	10
835	Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. <b>2014</b> , 108, 1525-33	28
834	Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies. <b>2014</b> , 20, 1634-40	28
833	Eosinophils from hematopoietic stem cell recipients suppress allogeneic T cell proliferation. <b>2014</b> , 20, 1891-8	11
832	Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. <b>2014</b> , 93, 1345-51	8
831	Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. <b>2014</b> , 49, 1070-5	28
830	Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. <b>2014</b> , 165, 673-81	45
829	T2(*) MRI changes in the heart and liver of ex-thalassemic patients after hematopoietic stem cell transplantation. <b>2014</b> , 7, 103-8	4
828	Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. <b>2014</b> , 99, 635-43	13
827	Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group. <b>2014</b> , 99, 644-51	8
826	Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study. <b>2014</b> , 31, 66	3
825	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <b>2014</b> , 20, 89-97	99
824	Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. <b>2014</b> , 15, 757-66	78
823	Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <b>2014</b> , 20, 1080-8	47



822	The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation. <b>2014</b> , 38, 334-9	5
821	Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?. <b>2014</b> , 20, 421-4	10
820	Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. <b>2014</b> , 20, 781-6	17
819	Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. <b>2014</b> , 20, 1217-23	28
818	Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <b>2014</b> , 20, 872-80	111
817	Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. <b>2014</b> , 42, 39-45	11
816	HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. <b>2014</b> , 20, 571-6	42
815	Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation. <b>2014</b> , 20, 106-110	38
814	Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. <b>2014</b> , 20, 556-63	27
813	Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. <b>2014</b> , 20, 951-9	30
812	Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. <b>2014</b> , 20, 370-4	37
811	Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. <b>2014</b> , 20, 1418-25	33
810	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. <b>2014</b> , 20, 1390-8	14
809	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <b>2014</b> , 22, 216-21	49
808	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <b>2014</b> , 124, 2596-606	184
807	Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. <b>2014</b> , 123, 1270-8	70
806	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <b>2014</b> , 124, 1372-7	142
805	Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. <b>2014</b> , 124, 2034-45	145

804	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <b>2014</b> , 124, 3817-27	128
803	Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. <b>2014</b> , 99, 1846-53	14
802	Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. <b>2015</b> , 37, 493-500	15
801	Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. <b>2015</b> , 55, 1993-2000	21
800	Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. <b>2015</b> , 126, 1027-32	63
799	Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. <b>2015</b> , 125, 1189-97	103
798	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. <b>2015</b> , 126, 1885-92; quiz 1970	56
797	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <b>2015</b> , 100, 683-9	29
796	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. <b>2015</b> , 100, 269-74	22
795	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. <b>2015</b> , 8, 116	27
794	Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. <b>2015</b> , 171, 585-94	108
793	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <b>2015</b> , 121, 3709-16	22
792	Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. <b>2015</b> , 62, 291-298	5
791	Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience. <b>2015</b> , 62, 2216-22	17
790	Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission. <b>2015</b> , 48, 871-6	4
789	Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. <b>2015</b> , 10, e1119595	10
788	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <b>2015</b> , 21, 1776-82	11
787	Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies. <b>2015</b> , 39, 625-31	4

786	The impact of pediatric blood and marrow transplant on parents: introduction of the parent impact scale. <b>2015</b> , 13, 46	6
785	Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <b>2015</b> , 21, 1605-11	28
784	Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. <b>2015</b> , 21, 1460-70	52
783	A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. <b>2015</b> , 102, 460-70	7
782	Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status. <b>2015</b> , 39, 1375-81	11
781	Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. <b>2015</b> , 16, 1585-94	20
780	Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. <b>2015</b> , 21, 2002-7	30
779	Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis. <b>2015</b> , 20, 313-9	2
778	Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning. <b>2015</b> , 20, 410-5	1
777	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. <b>2015</b> , 29, 396-405	98
776	Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. <b>2015</b> , 21, 473-82	58
775	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. <b>2015</b> , 21, 552-8	9
774	Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation. <b>2015</b> , 21, 483-8	4
773	Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years. <b>2015</b> , 21, 517-25	14
772	NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. <b>2015</b> , 21, 589-603	165
771	Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study. <b>2015</b> , 168, 518-25	18
770	Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. <b>2015</b> , 33, 364-9	41
769	Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. <b>2015</b> , 95, 455-60	28

768	CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease. <b>2015</b> , 21, 250-8	32
767	Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <b>2015</b> , 94, 663-9	3
766	Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation. <b>2015</b> , 141, 1089-94	5
765	Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant. <b>2015</b> , 31, 404-12	1
764	Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. <b>2015</b> , 21, 1106-9	107
763	Chronic Graft-Versus-Host Disease. <b>2015</b> , 245-258	
762	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <b>2015</b> , 21, 2115-2122	21
761	Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. <b>2015</b> , 50, 559-65	37
760	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <b>2015</b> , 21, 2091-2099	45
759	Association between thymic function and allogeneic hematopoietic stem cell transplantation outcome: results of a pediatric study. <b>2015</b> , 21, 1099-105	7
758	Minimal antileukaemic treatment followed by reduced-intensity conditioning in three consecutive children with Fanconi anaemia and AML. <b>2015</b> , 50, 463-4	5
757	Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites. <b>2015</b> , 50, 834-9	11
756	Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French-Swiss retrospective study. <b>2015</b> , 50, 1316-20	15
755	Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. <b>2015</b> , 141, 2193-203	5
754	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <b>2015</b> , 21, 1746-53	39
753	Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. <b>2015</b> , 15, 705-14	14
752	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. <b>2015</b> , 90, 144-8	22
751	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haematopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. <b>2015</b> , 2, e194-203	158

750	Few and nonsevere adverse infusion events using an automated method for diluting and washing before unrelated single cord blood transplantation. <b>2015</b> , 21, 682-7	5
749	Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. <b>2015</b> , 21, 640-5	21
748	Changing factors associated with parent activation after pediatric hematopoietic stem cell transplant. <b>2015</b> , 23, 1997-2006	7
747	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <b>2015</b> , 23, 1997-2006	8
746	Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. <b>2015</b> , 56, 999-1003	8
745	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <b>2015</b> , 21, 1589-96	31
744	Blood and Marrow Transplant Handbook. <b>2015</b> ,	5
743	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. <b>2015</b> , 50, 822-8	14
742	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <b>2015</b> , 21, 1790-5	6
741	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <b>2015</b> , 33, 4167-75	111
740	Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. <b>2015</b> , 50, 1476-9	0
739	A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants. <b>2015</b> , 168, 874-81	5
738	Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. <b>2015</b> , 169, 719-25	30
737	Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. <b>2015</b> , 169, 726-36	50
736	Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China. <b>2015</b> , 19, 413-21	6
735	Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. <b>2015</b> , 4, 113-126	12
734	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. <b>2015</b> , 21, 1783-9	68
733	Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. <b>2015</b> , 55, 736-47	18

732	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. <b>2015</b> , 102, 670-7	4
731	Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. <b>2015</b> , 94, 1727-32	12
730	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <b>2015</b> , 50, 1465-72	26
729	Clinical significance of the administration of cytarabine or thiotepea in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia. <b>2015</b> , 102, 451-9	3
728	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. <b>2015</b> , 21, 2129-2135	3
727	Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan. <b>2015</b> , 21, 1495-505	38
726	Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. <b>2015</b> , 29, 948-54	29
725	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <b>2015</b> , 21, 266-74	214
724	Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. <b>2015</b> , 90, E9-E16	52
723	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <b>2015</b> , 94, 449-55	7
722	Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. <b>2015</b> , 21, 55-9	26
721	Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. <b>2015</b> , 21, 180-4	10
720	Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. <b>2015</b> , 21, 89-96	9
719	Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. <b>2015</b> , 21, 97-104	115
718	Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. <b>2015</b> , 50, 127-33	25
717	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <b>2015</b> , 50, 197-203	27
716	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <b>2015</b> , 21, 2020-8	69
715	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups. <b>2015</b> , 136, 1697-707	33



714	Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. <b>2015</b> , 56, 663-70	13
713	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. <b>2015</b> , 56, 1058-65	11
712	Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. <b>2016</b> , 1, 152-159	12
711	The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation. <b>2016</b> , 57, 16-28	8
710	Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?. <b>2016</b> , 57, 6-15	8
709	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <b>2016</b> , 9, 89	24
708	The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. <b>2016</b> , 63, 743-51	8
707	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <b>2016</b> , 101, 256-62	33
706	Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia. <b>2016</b> , 20, 692-6	10
705	Hematopoietic stem cell transplantation for inborn errors of metabolism: A report from the Research Committee on Transplantation for Inborn Errors of Metabolism of the Japanese Ministry of Health, Labour and Welfare and the Working Group of the Japan Society for Hematopoietic Cell Transplantation. <b>2016</b> , 20, 203-14	15
704	Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <b>2016</b> , 173, 444-55	41
703	Improved Splenic Function After Hematopoietic Stem Cell Transplant for Sickle Cell Disease. <b>2016</b> , 63, 908-13	16
702	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <b>2016</b> , 174, 235-48	88
701	Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. <b>2016</b> , 97, 479-488	15
700	Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantation. <b>2016</b> ,	
699	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <b>2016</b> , 3, e526-e536	130
698	Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. <b>2016</b> , 128, 2734-2741	97
697	Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. <b>2016</b> , 101, 1592-1602	33



696	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. <b>2016</b> , 9, 65	12
695	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <b>2016</b> , 16, 379-86	15
694	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. <b>2016</b> , 22, 1056-1064	16
693	Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. <b>2016</b> , 22, 1473-1479	6
692	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <b>2016</b> , 51, 1307-1312	28
691	Cord Blood Units with High CD3(+) Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation. <b>2016</b> , 22, 1073-1079	10
690	Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. <b>2016</b> , 38, 99-105	
689	Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts. <b>2016</b> , 22, 815-24	18
688	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <b>2016</b> , 127, 938-47	206
687	Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. <b>2016</b> , 127, 3450-7	69
686	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <b>2016</b> , 101, 1251-1259	17
685	A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. <b>2016</b> , 22, 1844-1850	39
684	Management of Graft-Versus-Host Disease. <b>2016</b> , 1, 419-433	
683	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <b>2016</b> , 175, 841-850	38
682	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <b>2016</b> , 22, 1808-1815	18
681	Chronic Graft-versus-Host Disease Clinical Manifestations and Therapy. <b>2016</b> , 1020-1039	1
680	Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. <b>2016</b> , 22, 1781-1791	44
679	Experiences and preferences of patients visiting an otorhinolaryngology outpatient clinic: a qualitative study. <b>2016</b> , 19, 275-87	4

678	Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases. <b>2016</b> , 63, 2221-2229	6
677	Pathology of Transplantation. <b>2016</b> ,	1
676	Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. <b>2016</b> , 38, 60-6	3
675	Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. <b>2016</b> , 22, 2194-2200	25
674	Hematopoietic Stem Cell Transplantation. <b>2016</b> , 401-449	5
673	Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. <b>2016</b> , 128, 794-804	37
672	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. <b>2016</b> , 101, 884-90	23
671	Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. <b>2016</b> , 175, 265-274	75
670	Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. <b>2016</b> , 5, 3068-3076	8
669	Allogeneic hematopoietic stem cell transplantation for Chediak-Higashi syndrome. <b>2016</b> , 20, 271-5	7
668	Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. <b>2016</b> , 22, 1654-1663	28
667	Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning. <b>2016</b> , 22, 1627-1635	34
666	Cyclosporine Plus Methotrexate or Cyclosporine Plus Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Acute Leukemia Transplant: Comparison of Toxicity, Engraftment Kinetics and Transplant Outcome. <b>2016</b> , 32, 248-56	1
665	Early Lung Computed Tomography Scan after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2016</b> , 22, 1511-1516	2
664	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. <b>2016</b> , 47, 8-15	6
663	Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease. <b>2016</b> , 22, 1608-1614	39
662	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. <b>2016</b> , 9, 25	44
661	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <b>2016</b> , 34, 3141-9	170

660	A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease. <b>2016</b> , 22, 1664-1670	9
659	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. <b>2016</b> , 30, 170-8	8
658	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. <b>2016</b> , 34, 154-60	3
657	Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome. <b>2016</b> , 32, 32-8	6
656	Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. <b>2016</b> , 142, 317-24	10
655	Maternal microchimerism in health and disease. <b>2016</b> , 31, 121-30	19
654	Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. <b>2016</b> , 51, 654-62	8
653	Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. <b>2016</b> , 18, 172-85	35
652	Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center Study. <b>2016</b> , 22, 1087-1093	60
651	Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. <b>2016</b> , 103, 453-60	28
650	Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. <b>2016</b> , 51, 961-6	7
649	Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. <b>2016</b> , 51, 267-72	19
648	Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 51, 553-9	45
647	Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. <b>2016</b> , 51, 771-7	26
646	Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors. <b>2016</b> , 22, 134-40	52
645	Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes. <b>2016</b> , 22, 27-36	7
644	Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 51, 89-95	27
643	High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT. <b>2016</b> , 51, 110-8	31

642	Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. <b>2016</b> , 51, 186-93	33
641	Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. <b>2016</b> , 51, 58-66	31
640	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. <b>2016</b> , 96, 128-35	17
639	Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation. <b>2016</b> , 57, 103-9	5
638	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <b>2017</b> , 123, 2035-2042	11
637	Clinical management of genital chronic GvHD. <b>2017</b> , 52, 803-810	26
636	Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. <b>2017</b> , 10, 31	25
635	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <b>2017</b> , 123, 1828-1838	49
634	Histopathology of Cutaneous Graft-Versus-Host Disease. <b>2017</b> , 43-56	
633	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <b>2017</b> , 23, 618-624	54
632	Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. <b>2017</b> , 52, 592-599	25
631	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <b>2017</b> , 23, 767-775	27
630	Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. <b>2017</b> , 10, 25	92
629	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <b>2017</b> , 96, 805-815	8
628	Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience. <b>2017</b> , 47, 574-578	8
627	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <b>2017</b> , 23, 853-856	21
626	Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. <b>2017</b> , 21, e12890	2
625	A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. <b>2017</b> , 102, 1112-1119	23

624	Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. <b>2017</b> , 19, 735-743	3
623	The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. <b>2017</b> , 42, 34-39	3
622	Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia. <b>2017</b> , 123, 3346-3355	18
621	HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin). <b>2017</b> , 22, 129-135	11
620	Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <b>2017</b> , 28, 2191-2198	6
619	Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. <b>2017</b> , 23, 1437-1446	28
618	An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial. <b>2017</b> , 52, 1288-1293	11
617	The Impact of High-resolution HLA-A, HLA-B, HLA-C, and HLA-DRB1 on Transplant-related Outcomes in Single-unit Umbilical Cord Blood Transplantation in Pediatric Patients. <b>2017</b> , 39, 26-32	5
616	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <b>2017</b> , 10, 117	17
615	Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia. <b>2017</b> , 21, e12926	1
614	Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation. <b>2017</b> , 140, 1643-1650.e9	57
613	Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. <b>2017</b> , 123, 2867-2874	78
612	Role of Genetic Polymorphism of ALDH2 in Hematopoietic Stem Cell Transplantation. <b>2017</b> , 23, 1374-1380	1
611	Evolving concepts in prognostic scoring of chronic GvHD. <b>2017</b> , 52, 1361-1366	5
610	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. <b>2017</b> , 4, e183-e191	113
609	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <b>2017</b> , 23, 971-979	11
608	Improved survival after acute graft--host disease diagnosis in the modern era. <b>2017</b> , 102, 958-966	50
607	A Canine Model of Chronic Graft-versus-Host Disease. <b>2017</b> , 23, 420-427	9

606	Atlas of Graft-versus-Host Disease. <b>2017</b> ,	1
605	Classification systems for chronic graft-versus-host disease. <b>2017</b> , 129, 30-37	139
604	MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. <b>2017</b> , 23, 436-444	17
603	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. <b>2017</b> , 52, 400-408	32
602	Androgens in women after allogeneic hematopoietic cell transplantation: impact of chronic GvHD and glucocorticoid therapy. <b>2017</b> , 52, 431-437	4
601	Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. <b>2017</b> , 98, 363-370	8
600	Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia. <b>2017</b> , 65, 115-119	
599	Manual of Cardio-oncology. <b>2017</b> ,	1
598	Associations of interactions between NLRP3 SNPs and HLA mismatch with acute and extensive chronic graft-versus-host diseases. <b>2017</b> , 7, 13097	13
597	Isolated Testicular Recurrence of AML in Patients With Chronic GVHD >1 Year Following Allogeneic Stem Cell Transplant. <b>2017</b> , 39, e423-e425	0
596	Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. <b>2017</b> , 23, 2137-2142	8
595	Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. <b>2017</b> , 92, 1303-1310	28
594	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2017</b> , 23, 2070-2078	35
593	Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained. <b>2017</b> , 23, 1969-1997	9
592	Validation of International Chronic Ocular Graft-Versus-Host Disease (GVHD) Group Diagnostic Criteria as a Chronic Ocular GVHD-Specific Metric. <b>2017</b> , 36, 258-263	25
591	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2017</b> , 23, 1939-1948	14
590	Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series. <b>2017</b> , 23, 1767-1772	14
589	The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. <b>2017</b> , 17, 658-666	18



588	Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. <b>2017</b> , 96, 289-297	7
587	Pre-transplant donor CD4 invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. <b>2017</b> , 31, 903-912	30
586	Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation. <b>2017</b> , 58, 1403-1411	3
585	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <b>2017</b> , 23, 211-234	206
584	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <b>2017</b> , 92, 42-49	38
583	Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. <b>2017</b> , 31, e12880	0
582	Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. <b>2017</b> , 52, 20-27	28
581	Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience. <b>2017</b> , 7, 655	3
580	Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. <b>2017</b> , 377, 2565-2579	261
579	Genetic polymorphism related to monocyte-macrophage function is associated with graft-versus-host disease. <b>2017</b> , 7, 15666	14
578	A Comparison of Tacrolimus and Cyclosporine for Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors. <b>2017</b> , 6, 133-141	
577	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. <b>2017</b> , 95, 20-25	7
576	Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. <b>2017</b> , 1, 341-351	23
575	An update on the clinical utility of extracorporeal photopheresis in the treatment of graft-versus-host disease. <b>2017</b> , Volume 5, 19-28	1
574	Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. <b>2017</b> , 24, e123-e130	6
573	Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation. <b>2017</b> , 17, 123	14
572	Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation. <b>2017</b> , 18,	1
571	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <b>2017</b> , 35, 3002-3009	178



570	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. <b>2017</b> , 3, 773-781	9
569	Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). <b>2017</b> , 35, 2157-2164	122
568	Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities. <b>2018</b> , 24, 1455-1462	2
567	High incidence of BK virus-associated hemorrhagic cystitis in children after second or third allogeneic hematopoietic stem cell transplantation. <b>2018</b> , 22, e13183	8
566	Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. <b>2018</b> , 53, 1295-1303	11
565	Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma. <b>2018</b> , 144, 1173-1183	3
564	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <b>2018</b> , 124, 2541-2551	44
563	Danaparoid reduces transplant-related mortality in stem cell transplantation for children. <b>2018</b> , 22, e13099	4
562	Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial. <b>2018</b> , 53, 880-890	18
561	Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. <b>2018</b> , 53, 863-872	22
560	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <b>2018</b> , 24, 945-955	5
559	Allogeneic Hematopoietic Stem Cell Transplantation for Leukocyte Adhesion Deficiency. <b>2018</b> , 40, 137-140	4
558	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <b>2018</b> , 53, 431-437	23
557	Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. <b>2018</b> , 53, 417-421	1
556	Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. <b>2018</b> , 24, 1005-1012	32
555	Graft Source: Marrow or Peripheral Blood with Posttransplant Cyclophosphamide—What Matters?. <b>2018</b> , 111-125	
554	Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients. <b>2018</b> , 16, 352-367	28
553	Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol. <b>2018</b> , 97, e0449	11

552	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <b>2018</b> , 35, 79	8
551	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <b>2018</b> , 53, 1522-1531	13
550	Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation. <b>2018</b> , 108, 66-75	27
549	The European Blood and Marrow Transplantation Textbook for Nurses. <b>2018</b> ,	10
548	Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. <b>2018</b> , 61, 902-911	10
547	Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTM Trial. <b>2018</b> , 24, 1216-1222	13
546	Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome. <b>2018</b> , 36, 276-284	9
545	Confocal endomicroscopy in diagnosis of intestinal chronic graft-versus-host disease. <b>2018</b> , 36, 291-298	1
544	Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants. <b>2018</b> , 32, 492-498	32
543	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. <b>2018</b> , 48, 276-285	7
542	HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation. <b>2018</b> , 32, 168-175	31
541	Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. <b>2018</b> , 65, e26726	5
540	Bone Marrow Harvest in Pediatric Sibling Donors: Role of Granulocyte Colony-Stimulating Factor Priming and CD34 Cell Dose. <b>2018</b> , 24, 324-329	4
539	'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <b>2018</b> , 53, 58-63	4
538	Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignancies. <b>2018</b> , 53, 207-212	4
537	Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. <b>2018</b> , 107, 211-221	6
536	Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. <b>2018</b> , 53, 78-83	20
535	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <b>2018</b> , 24, 78-85	7

534	A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning. <b>2018</b> , 100, 335-343	6
533	Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience. <b>2018</b> , 100, 308-314	7
532	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <b>2018</b> , 24, 726-733	45
531	A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis. <b>2018</b> , 124, 727-733	4
530	Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. <b>2018</b> , 24, 827-831	1
529	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <b>2018</b> , 24, 521-528	19
528	Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. <b>2018</b> , 32, e13150	16
527	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2018</b> , 131, 2808-2816	5
526	Is Sjögren's syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests. <b>2018</b> , 13, e0208420	14
525	Transplantation Pathology. <b>2018</b> , 880-965	2
524	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <b>2018</b> , 11, 127	13
523	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. <b>2018</b> , 63, 1376-1382	21
522	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <b>2018</b> , 2, 1198-1206	17
521	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <b>2018</b> , 2, 2922-2936	17
520	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. <b>2018</b> , 2, 2095-2103	44
519	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. <b>2018</b> , 2, 49-60	25
518	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <b>2018</b> , 2, 1022-1031	8
517	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <b>2018</b> , 2, 299-307	47

516	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <b>2018</b> , 2, 1180-1186	23
515	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <b>2018</b> , 2, 933-940	23
514	Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. <b>2018</b> , 101, 332-339	7
513	Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. <b>2018</b> , 132, 750-754	34
512	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. <b>2018</b> , 24, 1866-1872	1
511	Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence. <b>2018</b> , 2018, 9451950	17
510	Potential Risks to Stable Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children With Cerebral X-linked Adrenoleukodystrophy. <b>2018</b> , 1, e180769	18
509	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <b>2018</b> , 97, 1975-1985	3
508	Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. <b>2018</b> , 24, 2450-2458	6
507	Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <b>2018</b> , 24, 2558-2567	24
506	Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease. <b>2018</b> , 9, 963	15
505	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <b>2018</b> , 22, 1118-1152	54
504	Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation. <b>2018</b> , 59, 263-275	5
503	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. <b>2018</b> , 183, 110-118	30
502	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <b>2018</b> , 24, 1828-1835	9
501	Haploidentical Transplantation. <b>2018</b> ,	
500	Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. <b>2018</b> , 24, 2487-2492	8
499	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <b>2018</b> , 53, 1401-1415	120

498	Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. <b>2019</b> , 54, 76-84	7
497	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <b>2019</b> , 25, 2383-2387	10
496	Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. <b>2019</b> , 25, 2438-2446	4
495	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <b>2019</b> , 25, 2388-2397	14
494	Pharmacotherapy in Pediatric Hematopoietic Cell Transplantation. <b>2020</b> , 261, 471-489	0
493	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. <b>2019</b> , 39, 653-667	21
492	Risk factors and clinical features for post-transplant thoracic air-leak syndrome in adult patients receiving allogeneic haematopoietic stem cell transplantation. <b>2019</b> , 9, 11795	3
491	Impairment of lung diffusion capacity-a new consequence in the long-term childhood leukaemia survivors. <b>2019</b> , 98, 2103-2110	4
490	Association of CD204 macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT. <b>2019</b> , 103, 578-587	2
489	Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. <b>2019</b> , 54, 1319-1326	17
488	How I treat refractory chronic graft-versus-host disease. <b>2019</b> , 133, 1191-1200	40
487	Pathology of Graft vs. Host Disease. <b>2019</b> ,	
486	Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. <b>2019</b> , 110, 347-354	3
485	Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <b>2019</b> , 25, 1993-2001	5
484	Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning. <b>2019</b> , 14, e0218945	7
483	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <b>2019</b> , 25, 1859-1868	37
482	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <b>2019</b> , 25, 1744-1755	4
481	Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. <b>2019</b> , 33, 2610-2618	7

480	Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis. <b>2019</b> , 44, 84-91	5
479	The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation. <b>2019</b> , 98, 1765-1773	3
478	Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. <b>2019</b> , 134, 304-316	31
477	Longitudinal analysis of meibomian gland dropout in patients with ocular graft-versus-host disease. <b>2019</b> , 17, 464-469	12
476	Clinical versus histological grading in the assessment of cutaneous graft versus host disease. <b>2019</b> , 24, 19	7
475	Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. <b>2019</b> , 14, e0213739	6
474	Hematopoietic stem cell transplantation in pediatric patients with $\beta$ -thalassemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). <b>2019</b> , 152, 135-140	
473	Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation. <b>2019</b> , 143, 1131-1143	5
472	Allogeneic Transplantation after Myeloablative Rituximab/BEAM + Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. <b>2019</b> , 25, 1347-1354	0
471	Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups. <b>2019</b> , 25, 1536-1543	10
470	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <b>2019</b> , 25, 1424-1431	9
469	A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. <b>2019</b> , 12, 311-323	10
468	Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation. <b>2019</b> , 103, 10-17	10
467	Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms. <b>2019</b> , 51, 896-900	
466	Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. <b>2019</b> , 12, 295-309	6
465	Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle. <b>2019</b> , 257, 1341-1351	36
464	Manifestations of Chronic GVHD in Other Organ Systems. <b>2019</b> , 237-244	
463	Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. <b>2019</b> , 54, 1489-1498	7

462	Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study. <b>2019</b> , 47, 275-284	7
461	Decline of forced expiratory volume in 1's after allogeneic hematopoietic cell transplantation is a good indicator for pulmonary damage and is associated with busulfan use. <b>2019</b> , 109, 299-308	2
460	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <b>2019</b> , 3, 1441-1449	7
459	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <b>2019</b> , 3, 2836-2844	24
458	The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. <b>2019</b> , 3, 1118-1128	26
457	High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. <b>2019</b> , 3, 397-405	6
456	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <b>2019</b> , 3, 360-369	59
455	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. <b>2019</b> , 3, 1950-1960	7
454	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <b>2019</b> , 3, 1750-1760	4
453	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. <b>2019</b> , 3, 2581-2585	10
452	Graft-Versus-Host Disease. <b>2019</b> , 2067-2077	
451	Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. <b>2019</b> , 2, e62	2
450	Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT). <b>2019</b> , 46, 370-375	1
449	Allogeneic transplantation in elderly patients ≥5 years with non-Hodgkin lymphoma: a time-trend analysis. <b>2019</b> , 9, 97	6
448	In Vitro Mesenchymal Progenitor Cell Expansion is a Predictor of Transplant-related Mortality and acute GvHD III-IV After Bone Marrow Transplantation in Univariate Analysis: A Large Single-Center Experience. <b>2019</b> , 41, 42-46	4
447	Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients. <b>2019</b> , 25, 293-300	6
446	Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. <b>2019</b> , 25, 664-672	3
445	Graft-versus-host disease. <b>2019</b> , 152, 22-28	9



444	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <b>2019</b> , 54, 1237-1244	5
443	The Association of Performance Status and Disease Severity in Patients With Chronic Graft-vs-Host Disease. <b>2019</b> , 100, 606-612	5
442	Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. <b>2019</b> , 25, 949-954	5
441	Graft-versus-host disease. <b>2019</b> , 152, 22-28	0
440	Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin. <b>2019</b> , 102, 256-264	12
439	Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <b>2019</b> , 62, 418-427	2
438	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <b>2019</b> , 12, 6	15
437	Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogeneic stem cell transplantation. <b>2019</b> , 60, 2056-2061	1
436	Hematopoietic stem cell transplantation in pediatric patients with thalassemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON). <b>2019</b> , 152, 135-140	4
435	Recipient Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy. <b>2019</b> , 20,	4
434	Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. <b>2019</b> , 54, 894-902	7
433	Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning. <b>2019</b> , 54, 1227-1236	5
432	Allogeneic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy. <b>2019</b> , 18, 1-6	10
431	Reassessment of clinical implication of pretransplant surgical procedures for pulmonary invasive fungal lesions. <b>2019</b> , 21, e13023	1
430	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. <b>2019</b> , 54, 1198-1207	5
429	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. <b>2019</b> , 102, 331-340	4
428	Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. <b>2019</b> , 25, 912-920	3
427	Challenges in managing graft-versus-host disease in developing countries: a perspective. <b>2019</b> , 54, 641-647	4

426	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <b>2019</b> , 25, 301-306	14
425	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <b>2019</b> , 25, 270-278	14
424	Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). <b>2019</b> , 25, 328-334	4
423	Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia. <b>2019</b> , 25, e55-e59	9
422	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <b>2019</b> , 104, 380-391	19
421	Risk Factors Analysis for Human Cytomegalovirus Viremia in Donor+/Recipient+ Hematopoietic Stem Cell Transplantation. <b>2020</b> , 51, 74-79	3
420	TLI in pediatric patients. <b>2020</b> , 22, 884-891	5
419	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. <b>2020</b> , 55, 224-232	5
418	Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation. <b>2020</b> , 55, 384-392	12
417	Lower limb pain following allogeneic hematopoietic stem cell transplantation in Japanese children. <b>2020</b> , 25, 682-687	
416	Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. <b>2020</b> , 55, 409-418	3
415	Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens. <b>2020</b> , 55, 1638-1641	2
414	Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose?. <b>2020</b> , 55, 505-522	9
413	Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children. <b>2020</b> , 26, 114-122	10
412	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. <b>2020</b> , 34, 87-99	11
411	Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group. <b>2020</b> , 26, 66-75	2
410	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <b>2020</b> , 26, 83-87	1
409	Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. <b>2020</b> , 189, 153-161	4

408	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <b>2020</b> , 55, 633-640	2
407	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <b>2020</b> , 34, 1144-1153	4
406	Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. <b>2020</b> , 20, 677-688	3
405	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <b>2020</b> , 26, 358-366	20
404	A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. <b>2020</b> , 26, 162-170	3
403	Chronic Graft Versus Host Myopathies: Noninflammatory, Multi-Tissue Pathology With Glycosylation Disorders. <b>2020</b> , 79, 102-112	4
402	Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. <b>2020</b> , 95, 251-257	3
401	Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study. <b>2020</b> , 33, 391-401	0
400	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. <b>2020</b> , 6, 486-493	19
399	The kidney injury caused by the onset of acute graft-versus-host disease is associated with down-regulation of $\beta$ Klotho. <b>2020</b> , 78, 106042	2
398	Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia. <b>2020</b> , 99, 147-155	4
397	Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation. <b>2020</b> , 61, 840-847	5
396	Partially CD3-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. <b>2020</b> , 26, 493-501	2
395	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. <b>2020</b> , 24, e13864	2
394	Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. <b>2020</b> , 4, 4748-4757	5
393	Hematopoietic stem cell transplantation in children and adolescents with nonremission acute lymphoblastic leukemia. <b>2020</b> , 67, e28732	1
392	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <b>2020</b> , 26, 2252-2261	1
391	High-dose post-transplant cyclophosphamide impairs T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. <b>2020</b> , 9, e1171	4

390	Topical Corticosteroids a Viable Solution for Oral Graft Versus Host Disease? A Systematic Insight on Randomized Clinical Trials. <b>2020</b> , 56,	
389	Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <b>2020</b> , 61, 2839-2849	10
388	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. <b>2020</b> , 26, 1930-1936	5
387	Histopathological Grading of Oral Mucosal Chronic Graft-versus-Host Disease: Large Cohort Analysis. <b>2020</b> , 26, 1971-1979	1
386	Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <b>2020</b> , 95, 1200	6
385	Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 99, 1655-1665	6
384	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <b>2020</b> , 26, 2237-2244	5
383	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <b>2020</b> , 26, 1655-1662	2
382	Dermoscopy of Cutaneous Graft-Versus-Host-Disease in Patients After Allogeneic Hematopoietic Stem Cell Transplantation. <b>2020</b> , 10, 1043-1061	2
381	Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation. <b>2020</b> , 26, 1689-1696	3
380	Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. <b>2020</b> , 112, 510-523	6
379	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <b>2020</b> , 26, e322-e327	19
378	Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant. <b>2020</b> , 10, 573822	12
377	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. <b>2020</b> , 99, 2393-2404	2
376	Steroid-refractory acute graft-versus-host disease graded III-IV in pediatric patients. A mono-institutional experience with a long-term follow-up. <b>2020</b> , 24, e13806	1
375	Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. <b>2020</b> , 112, 825-834	1
374	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <b>2020</b> , 38, 2062-2076	19
373	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 55, 2087-2097	3

372	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <b>2020</b> , 55, 2147-2159	11
371	Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model. <b>2020</b> , 18, 471-483	2
370	Individual HLA alleles and risk of graft-versus-host disease after haematopoietic stem cell transplantation from HLA-identical siblings. <b>2020</b> , 75, 2045-2052	
369	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <b>2020</b> , 26, 1697-1703	3
368	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <b>2020</b> , 104, 1070-1080	3
367	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <b>2020</b> , 6, 1011-1018	19
366	Financial impact of post-transplant complications among children undergoing allogeneic hematopoietic cell transplantation. <b>2020</b> , 55, 1421-1429	2
365	Comparative Study of Mizoribine and Mycophenolate Mofetil Combined with a Calcineurin Inhibitor-Based Immunosuppressive Regimen in Patients with Alternative Donor Hematopoietic Cell Transplantation. <b>2020</b> , 26, 1663-1669	2
364	Immune Modulation Properties of Zoledronic Acid on TcR $\alpha$ -Lymphocytes After TcR $\alpha$ /CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia. <b>2020</b> , 11, 699	10
363	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. <b>2020</b> , 55, 1955-1965	2
362	Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD. <b>2020</b> , 11, 19	3
361	Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. <b>2020</b> , 136, 1201-1211	36
360	Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia. <b>2020</b> , 55, 1068-1075	3
359	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <b>2020</b> , 26, 1084-1090	11
358	Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients. <b>2020</b> , 12,	6
357	The Fetal-Maternal Immune Interface in Uterus Transplantation. <b>2020</b> , 41, 213-224	4
356	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <b>2020</b> , 26, 1113-1118	3
355	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <b>2020</b> , 26, 1137-1143	7

354	Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. <b>2020</b> , 63, 1552-1564	6
353	A high CD34 cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. <b>2020</b> , 55, 1726-1735	2
352	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. <b>2020</b> , 55, 1337-1346	4
351	Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. <b>2020</b> , 111, 869-876	1
350	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. <b>2020</b> , 26, 998-1004	3
349	NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <b>2020</b> , 99, 609-618	1
348	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <b>2020</b> , 190, 573-582	7
347	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <b>2020</b> , 26, 1312-1317	27
346	The predictive value of serum free light chain level early after allogeneic hematopoietic stem cell transplantation for chronic graft-versus-host disease, a preliminary study. <b>2020</b> , 34, e13865	
345	Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial. <b>2020</b> , 9, 5	2
344	Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation. <b>2020</b> , 59, 102743	1
343	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <b>2020</b> , 34, 3338-3347	15
342	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <b>2021</b> , 35, 215-224	15
341	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <b>2021</b> , 56, 20-29	0
340	CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. <b>2021</b> , 137, 848-855	4
339	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <b>2021</b> , 27, 843-851	11
338	Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia. <b>2021</b> , 100, 217-228	1
337	Outcomes of second hematopoietic stem cell transplantation using reduced-intensity conditioning in an outpatient setting. <b>2021</b> , 39, 87-96	1



336	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <b>2021</b> , 27, 58-66	5
335	Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. <b>2021</b> , 27, 70.e1-70.e8	
334	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. <b>2021</b> , 35, e14160	1
333	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <b>2021</b> , 27, 171.e1-171.e8	2
332	Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. <b>2021</b> , 10, 542-553	4
331	Outcome of chronic granulomatous disease - Conventional treatment vs stem cell transplantation. <b>2021</b> , 32, 576-585	5
330	Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia. <b>2021</b> , 56, 1013-1020	4
329	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with paroxysmal nocturnal hemoglobinuria. <b>2021</b> , 113, 122-127	2
328	Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation. <b>2021</b> , 113, 556-565	2
327	Biology of Graft-Versus-Host Disease. <b>2021</b> , 55-73	
326	Donor UNC-93 Homolog B1 genetic polymorphism predicts survival outcomes after unrelated bone marrow transplantation. <b>2021</b> , 22, 35-43	1
325	Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <b>2021</b> , 56, 1593-1602	1
324	High preharvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation. <b>2021</b> , 106, 643-653	1
323	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <b>2021</b> , 27, 255.e1-255.e9	1
322	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <b>2021</b> , 100, 1311-1319	
321	Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. <b>2021</b> , 39, 768-778	25
320	The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III $\beta$ -thalassemia major. <b>2021</b> , 12, 213	0
319	Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT. <b>2021</b> , 96, 571-579	3



318	Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. <b>2021</b> , 114, 263-270	0
317	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <b>2021</b> , 56, 1998-2004	3
316	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2021</b> , 14, 53	9
315	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <b>2021</b> , 56, 2005-2012	1
314	Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. <b>2021</b> , 11, 8501	2
313	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. <b>2021</b> , 11, 88	1
312	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <b>2021</b> , 14, 76	2
311	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <b>2021</b> , 27, 410-422	4
310	Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts. <b>2021</b> , 10, 1552-1565	0
309	Race as a factor in donor selection and survival of children with hematologic malignancies undergoing hematopoietic stem cell transplant in Florida. <b>2021</b> , 68, e29180	
308	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. <b>2021</b> , 7, e724	0
307	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <b>2021</b> , 96, 1186-1194	1
306	Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. <b>2021</b> , 12, 695037	0
305	A Review of Ocular Graft-versus-Host Disease: Pathophysiology, Clinical Presentation and Management. <b>2021</b> , 1-10	4
304	Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. <b>2021</b> , 56, 2797-2803	0
303	Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation. <b>2021</b> , 227, 25-34	8
302	Impact of decontamination therapy on gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in children: Decontamination therapy in allo-HCT. <b>2021</b> , 69, 103298	2
301	Single-Arm Non-Blinded Multicenter Clinical Trial on T-Cell-Replete Haploidentical Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin for Relapsed and Refractory Pediatric Acute Leukemia. <b>2021</b> , 66, 161-168	

300	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. <b>2021</b> , 56, 2964-2974	0
299	Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients. <b>2021</b> , 27, 686.e1-686.e9	
298	Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. <b>2021</b> , 100, 2763-2771	0
297	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <b>2021</b> , 27, 5847-5856	0
296	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. <b>2021</b> , 5, 3528-3539	6
295	[Cutaneous complications following hematopoietic stem cell transplantation]. <b>2021</b> , 108, 877-885	
294	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <b>2021</b> ,	0
293	Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation-A Matched-Pair Analysis. <b>2021</b> ,	0
292	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <b>2021</b> , 195, 417-428	2
291	Graft Versus Host Disease: Management of Acute and Chronic Disease. <b>2021</b> , 365-393	
290	Health-related quality of life in pediatric bone marrow transplant survivors: According to whom?. <b>1999</b> , 83, 46-51	14
289	Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. <b>2018</b> , 93, 47-57	9
288	Biology and management of chronic graft-versus-host disease. <b>2009</b> , 144, 277-98	7
287	Chronic Graft-versus-Host Disease: Pathogenesis, Diagnosis, Treatment, and Prognostic Factors. <b>1988</b> , 150-157	6
286	Recapitulation of immune ontogeny: a vital component for the success of bone marrow transplantation. <b>1990</b> , 50, 27-54	6
285	Chronic graft-versus-host disease. <b>1990</b> , 50, 79-98	10
284	Head and Neck Complications of Bone Marrow Transplantation. <b>1986</b> , 401-427	10
283	Oral Complications of Bone-Marrow Transplantation. <b>1983</b> , 93-112	11

282	Allograft Transplant cancer Registry. <b>1984</b> , 281-308	5
281	Lymphoproliferative Diseases and Kaposi's Sarcoma in Homosexual Males. <b>1984</b> , 385-400	1
280	Acute Graft-vs-Host Disease. <b>2004</b> , 159-184	1
279	Chronic Graft-Versus-Host Disease. <b>2010</b> , 577-595	1
278	Graft-Versus-Host Disease (GvHD). <b>2018</b> , 221-251	4
277	Prelymphoma, early lymphoma, and manifest lymphoma in immunosialadenitis (Sjögren's syndrome)--a model of lymphomagenesis. <b>1983</b> , 28, 418-22	4
276	Allogeneic bone marrow transplantation in leukemia. <b>1984</b> , 93, 269-89	1
275	Ocular Graft-versus-Host Disease. <b>2011</b> , 789-796	1
274	Association of Inflammatory Myopathies with Other Connective Tissue Disorders and Malignancies. <b>1988</b> , 37-69	1
273	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <b>2020</b> , 26, 1099-1105	3
272	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <b>2020</b> , 26, 1459-1468	14
271	Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients. <b>2020</b> , 26, 2262-2270	1
270	Predicted indirectly recognizable HLA epitopes are not associated with clinical outcomes after haploidentical hematopoietic stem cell transplantation. <b>2018</b> , 79, 117-121	5
269	The pathophysiology and treatment of graft-versus-host disease. <b>1983</b> , 12, 775-89	84
268	Therapeutic Plasma Exchange: Dermatologic Applications. <b>1983</b> , 1, 571-589	6
267	Animal Models of Fibrosis. <b>1990</b> , 16, 153-167	17
266	Graft-versus-host disease in children. <b>1995</b> , 14, 66-9	8
265	Hematopoietic stem cell transplantation. 599-624	2

264	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <b>2020</b> , 34, 2766-2775	10
263	Weight loss and malnutrition in patients with chronic graft-versus-host disease.	1
262	A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation.	2
261	Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.	2
260	Cytomegalovirus-induced CD13-specific autoimmunity--a possible cause of chronic graft-vs-host disease. <b>1996</b> , 61, 600-9	68
259	Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. <b>1996</b> , 61, 826-30	10
258	Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. <b>1997</b> , 63, 854-60	60
257	Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. <b>1998</b> , 66, 620-5	56
256	Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. <b>1999</b> , 67, 59-65	59
255	Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. <b>1999</b> , 67, 1425-33	21
254	Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients. <b>2000</b> , 69, 1582-6	20
253	The Overlap Syndrome: A Case Report of Chronic Graft-Versus-Host Disease After the Development of a Pseudomembrane. <b>2021</b> , 40, 1188-1192	1
252	Treatment of Children With Cancer and/or Hematopoietic Stem Cell Transplantation in the Intensive Care Unit: Experience at a Large European Pediatric Cancer Center. <b>2020</b> , 42, e583-e588	4
251	B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. <b>2008</b> , 85, 386-90	31
250	Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. <b>1996</b> , 134, 848-854	40
249	Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. <b>1996</b> , 134, 780-783	18
248	High levels of anti-cytoskeleton autoantibodies are frequently associated with chronic GVHD. <b>1987</b> , 67, 301-5	12
247	Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjögren syndrome and scleroderma. <b>1987</b> , 66, 45-7	58

246	Therapeutic efficiency of platelet gel for the treatment of oral ulcers related to chronic graft versus host disease after allogeneic haematopoietic stem cell transplantation. <b>2017</b> , 10, 398-405	4
245	Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. <b>1986</b> , 77, 1584-95	115
244	B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. <b>1987</b> , 80, 325-32	56
243	Successful Correction of Hemophagocytic Lymphohistiocytosis With Related or Unrelated Bone Marrow Transplantation. <b>1997</b> , 89, 3857-3863	2
242	Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant. <b>1997</b> , 89, 3864-3872	3
241	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <b>1997</b> , 90, 4705-4709	7
240	T-Cell Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. <b>1998</b> , 91, 1083-1090	2
239	Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia. <b>1998</b> , 92, 4072-4079	3
238	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <b>1998</b> , 92, 1910-1917	3
237	Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host Disease. <b>1998</b> , 92, 3098-3104	7
236	T-Cell Depletion Plus Salvage Immunotherapy With Donor Leukocyte Infusions as a Strategy to Treat Chronic-Phase Chronic Myelogenous Leukemia Patients Undergoing HLA-Identical Sibling Marrow Transplantation. <b>1999</b> , 94, 434-441	1
235	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <b>2001</b> , 97, 631-637	5
234	How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. <b>2020</b> , 4, 6283-6290	16
233	Respiratory viruses in immunocompromised hosts Laurent Kaiser. <b>2003</b> , 298-331	6
232	Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin. <b>2019</b> , 24, 461-471	4
231	Lymphotropic herpesvirus DNA detection in patients with active CMV infection - a possible role in the course of CMV infection after hematopoietic stem cell transplantation. <b>2011</b> , 17, CR432-441	10
230	Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy. <b>2013</b> , 22, 53-64	12
229	Abnormal Adipose Tissue Distribution with Unfavorable Metabolic Profile in Five Children Following Hematopoietic Stem Cell Transplantation: A New Etiology for Acquired Partial Lipodystrophy. <b>2013</b> , 22, 53-64	21

228	A risk prediction score for invasive mold disease in patients with hematological malignancies. <b>2013</b> , 8, e75531	45
227	Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. <b>2017</b> , 8, 27645-27660	9
226	Toll-like receptor genetic variations in bone marrow transplantation. <b>2017</b> , 8, 45670-45686	5
225	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <b>2018</b> , 9, 36603-36612	5
224	High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <b>2016</b> , 7, 27255-66	40
223	Cutaneous manifestations of acute and chronic graft-versus-host disease. <b>2020</b> , 155, 76-87	3
222	The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. <b>2012</b> , 10, 174-80	29
221	Challenges in Conducting Studies in Chronic Graft-Host Disease. <b>2019</b> , 1, 36-44	2
220	Autopsy findings in bone marrow transplantation. <b>1982</b> , 14, 197-204	11
219	Hematopoietic stem cell transplantation : overview for general pediatrician. <b>2007</b> , 50, 613	5
218	Comparison of total body irradiation-based or non-total body irradiation-based conditioning regimens for allogeneic stem cell transplantation in pediatric leukemia patients. <b>2010</b> , 53, 538	8
217	Clinical significance of platelet count at day +60 after allogeneic peripheral blood stem cell transplantation. <b>2006</b> , 21, 46-51	16
216	Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. <b>2006</b> , 21, 199-207	20
215	Effects of total body irradiation-based conditioning on allogeneic stem cell transplantation for pediatric acute leukemia: a single-institution study. <b>2014</b> , 32, 198-207	9
214	Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy. <b>2012</b> , 27, 72-83	1
213	Otolith shape analysis as a tool for stock discrimination of the black scabbardfish, <i>Aphanopus carbo</i> Lowe, 1839 (Pisces: Trichiuridae), in Portuguese waters. <b>2009</b> , 73, 47-53	18
212	Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia. <b>2015</b> , 128, 20-4	7
211	A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials. <b>2011</b> , 33, 283-289	6

210	Early lymphocyte recovery as a predictor of outcome, including relapse, after hematopoietic stem cell transplantation. <b>2012</b> , 34, 430-5	2
209	Bone marrow transplantation in 33 patients with malignant blood diseases and severe aplastic anaemia. <b>1983</b> , 2, 120-5	13
208	Bone-marrow transplantation for haematological malignancy in childhood. <b>1986</b> , 144, 347-50	3
207	Bone marrow transplantation: a review of a programme and its first 100 patients. <b>1990</b> , 153, 580-4	7
206	Graft Versus Host Disease. <b>2021</b> , 1-23	
205	Allogeneic Transplant and CAR-T Therapy After Autologous Transplant Failure in DLBCL: A Noncomparative Cohort Analysis. <b>2021</b> ,	4
204	Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 11, 708727	1
203	Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan. <b>2021</b> , 26, e14125	0
202	Commentary on and reprint of Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant Team, Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation, in New England Journal of Medicine (1981) 304:1529-1533. <b>2000</b> , 741-747	0
201	Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. <b>2000</b> , 96, 2391-2398	
200	Autoimmunity Caused by Oxidizing Foreign Compounds. <b>2001</b> ,	
199	Grading and Management of Graft-vs-Host Disease. <b>2003</b> , 237-260	1
198	Chronic Graft-vs-Host Disease After Transplantation. <b>2004</b> , 185-200	
197	Variable Number of Tandem Repeats (VNTR) Disparity between Donor and Recipient has a Potential to Predict the Outcomes of HLA-identical Allogeneic Stem Cell Transplantation. <b>2005</b> , 40, 231	
196	Hematopoietic Stem Cell Transplantation in Pediatric Acute Myelogenous Leukemia: Relevance of the Stem Cell Source to the Transplant Outcome. <b>2005</b> , 40, 242	
195	Impact of Day +11 Methotrexate on the Incidence of Graft-versus-host Disease after HLA-identical Allogeneic Peripheral Blood Stem Cell Transplantation. <b>2006</b> , 41, 73	
194	Graft-Versus-Host Disease and the Liver. <b>2006</b> , 863-874	
193	Outcome of Hematopoietic Stem Cell Transplantation: In Children and Adolescent Patients at Yeungnam University Hospital. <b>2007</b> , 42, 317	1



192 Graft versus Host Disease. **2008**, 4821-4830

191 A Case of Chronic Graft-versus-Host Disease (GVHD) with Various Skin Lesions. **2008**, 70, 381-386

190 Chronic Graft-versus-Host Disease. **2008**, 621-649

189 Hematopoietic Stem Cell Transplantation. **2008**, 501-512

1

188 Manifestations of Immunodeficiency in the GI Tract. **2009**, 81-96

0

187 Gastrointestinal Tract. **2009**, 1213-1371

1

186 Graft-Versus-Host Disease. **2010**, 433-441

185 Retrospective Analysis of 50 Cases of First Allogeneic Transplantation for Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome. **2010**, 59, 105-113

184 Retrospective Analysis of Reduced Intensity Conditioning Stem Cell Transplantation for Hematological Malignancies. **2010**, 59, 63-70

183 Gastrointestinal and Hepatic Complications of Solid Organ and Hematopoietic Cell Transplantation. **2010**, 537-555.e6

1

182 Acute Toxicities, Late Sequelae, and Quality of Survivorship in Children with Acute Myeloid Leukemia: The Impact of Allogeneic Stem Cell Transplant. **2011**, 265-282

181 Pleural Effusions and Thoracentesis in Patients with Hematological Malignancies. **2011**, 191-208

180 Management of Chronic Graft-versus-Host Disease 2012. **2012**, 1, 37-51

1

179 Clinical Significance of Pulmonary Function Tests in Long-Term Survivors after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. **2013**, 03, 6-12

178 Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease. 281-294

177 [Allogeneic stem-cell transplantation in adults 1985-2012: results and development]. **2014**, 134, 1569-75

176 Total Hip Arthroplasty in Very Young Bone Marrow Transplant Patients. **2014**, 4, 19-23

175 Klinische Immunologie. **1982**, 605-629

- 174 Role of Lymphocytes in Graft-Versus-Host Disease and its Prevention. **1984**, 57-64
- 173 Bone Marrow Transplantation for Neoplasia in Man. **1984**, 207-237
- 172 Ocular Manifestations of Graft-Versus-Host Disease Following Bone Marrow Transplantation. **1985**, 142-144
- 171 Comparative Value of Clinical Examination, Lip Biopsy and Salivary Scintigraphy for Detecting Sjogren-Like Syndrome in Bone Marrow Transplanted Patients. **1985**, 138-138
- 170 Scleroderma as a Fibrotic Disorder. **1985**, 397-423
- 169 Principles of Bone Marrow Transplantation. **1986**, 129-139
- 168 Inzidenz maligner Lymphome bei der myoepithelialen Sialadenitis. **1988**, 167-175 2
- 167 Predictive Factors for Chronic Graft-versus-Host Disease and Leukemic Relapse After Allogeneic Bone Marrow Transplantation. **1988**, 161-164
- 166 Chronic Graft-Versus-Host Disease. **1988**, 156-169
- 165 Immunological Injury to the Intestine and Liver in Human Marrow Transplant Recipients. **1989**, 159-173
- 164 The Immunocompromised Host. **1990**, 240-256
- 163 Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. **1990**, 90, 835-842 40
- 162 Chronic Graft-Versus-Host Disease. **1992**, 237-256
- 161 Skin lesion and differential diagnosis of chronic GVHD.. **1992**, 54, 3-6
- 160 Nuclear ADP-Ribosyltransferase as Target Antigen in Chronic Graft-Versus-Host Disease. **1992**, 251-255
- 159 Case report: acute polymyositis in a patient with chronic graft vs. host disease. **1992**, 9, 149-50 9
- 158 Bone marrow transplantation. **1996**, 3-12
- 157 Late effects of cancer therapy. **1997**, 92, 343-75

- 156 Scleroderma-Like Chronic GVHD Associated with Antiphospholipid Syndrome.. **1998**, 60, 54-57 1
- 155 Hurler Syndrome: II. Outcome of HLA-Genotypically Identical Sibling and HLA-Haploidentical Related Donor Bone Marrow Transplantation in Fifty-Four Children. **1998**, 91, 2601-2608
- 154 High Risk of Chronic Graft-Versus-Host Disease in Unmanipulated Allogeneic Peripheral Blood Stem Cell Transplantation. **1998**, 92, 2973-2975
- 153 Chronic Graft-Versus-Host Disease. **1999**, 183-198
- 152 Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management. **1999**, 93, 1127-1136 1
- 151 Peripheral Blood Stem Cell Transplantation From Unrelated Donors: A Comparison With Marrow Transplantation. **1999**, 94, 455-464
- 150 Hematopoietic Stem Cell Transplant. **2015**, 179-208
- 149 Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies. **2015**, 21, 2257-65
- 148 Tacrolimus and Mini-dose Methotrexate for Prevention of Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation in Children: A Single-center Study in Korea. **2015**, 22, 120-126
- 147 Ocular Graft versus Host Disease: A Review of Clinical Manifestations, Diagnostic Approaches and Treatment. **2016**, 06, 20-33
- 146 The Influence of Lymphoid Reconstitution Kinetics on Clinical Outcomes in Allogeneic Stem Cell Transplantation.
- 145 Outcomes of Hematopoietic Stem Cell Transplantation by Donor Types in Children with Acute Myeloid Leukemia. **2016**, 23, 145-157
- 144 Hematopoietic Stem Cell Transplantation and Cardiotoxicity. **2017**, 277-289
- 143 Cutaneous Graft-Versus-Host Disease. **2017**, 665-683
- 142 Myeloablative Hematopoietic Stem Cell Transplantation with a Non-total Body Irradiation Regimen for Treating Pediatric Acute Lymphoblastic Leukemia. **2017**, 24, 55-63
- 141 Musculoskeletal chronic graft versus host disease - A rare complication of allogeneic hematopoietic stem cell transplantation: A case report and review of its literature. **2017**, 6, 150 0
- 140 Retrospective Study of Sinusitis after Hematopoietic Stem Cell Transplant. **2018**, 57, 605-610
- 139 The thoracic air-leak syndrome (TALS): the frequency of occurrence and radiological signs in the structure of late non-infectious lung lesions in children after the allogeneic HSCT. **2019**, 18, 92-102 1

- 138 «Graft-Versus-Host» Disease after Haploidentical Hematopoietic Stem Cell Transplantation from Relative Donors in Children with Cancer, Prophylaxis Regimens and Correlation with «Graft-Versus-Tumor» Effect: a Retrospective Cohort Study. **2019**, 6, 113-122
- 137 Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis. **2020**, 59, 1947-1956 0
- 136 Ruxolitinib As a Salvage Therapy for Acute and Chronic Graft-versus-Host Disease in Children and Young Adults: a single institution experience..
- 135 Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. **2021**, 0
- 134 Monoclonal Antilymphocyte Antibodies: Probes for the Study of the Regulation of Hematopoiesis and Potential Clinical Applications<sup>11</sup>This work was supported by PHS Grant HL17265, awarded by the National Heart Lung Blood Institute, and Grants CA 18029, CA 29548, and Ca 30924 awarded by the National Cancer Institute, DHHS.. **1983**, 21-46
- 133 Graft Versus Host Disease: Management of Acute and Chronic Disease. **2021**, 1-30
- 132 Allogeneic Haemopoietic Stem Cell Transplantation. **2021**, 255-277
- 131 Polymorphism Impacts Proinflammatory Cytokine Levels, Survival, and Transplant-Related Mortality After Hematopoietic Stem Cell Transplantation in Adult Patients Receiving Busulfan-Based Conditioning Regimens. **2020**, 11, 563321 0
- 130 Biology of Graft-Versus-Host Disease. **2020**, 1-19
- 129 Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. **2020**, 35, 429-437 1
- 128 Does allogeneic stem cell transplantation in survivors of pediatric leukemia impact regular physical activity, pulmonary function, and exercise capacity?. **2021**, 8, 16
- 127 Disease of the liver following bone marrow transplantation in children: incidence, clinical course and outcome in a long-term perspective. **1998**, 87, 579-83 3
- 126 Contemporary Liver Immunology and Immunopathology. **2007**, 1-11
- 125 Graft-Versus-Host Disease. **2008**, 439-457
- 124 Bone Marrow Transplantation for the Treatment of Severe Aplastic Anaemia. **1983**, 12, 285-310 1
- 123 [Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia]. **2017**, 38, 761-766 1
- 122 Syndrome resembling graft-versus-host disease in a patient with disseminated carcinoma. **1983**, 76, 703-5 1
- 121 Bone marrow transplantation in man. Analysis of T and B cell functions in PWM driven Ig production. **1984**, 57, 467-78 1

120	Diseases caused by reactions of T lymphocytes to incompatible structures of the major histocompatibility complex. IV. Autoantibodies to nuclear antigens. <b>1981</b> , 46, 589-96	18
119	Depressed immunity and the development of cancer. <b>1981</b> , 46, 459-74	118
118	Immunoglobulin production after marrow transplantation. III. The functional heterogeneity of FC-IgG receptor positive and negative T cell subpopulations. <b>1982</b> , 48, 675-84	6
117	Lymphocytic infiltration and HLA-DR expression of salivary glands in bone marrow transplant recipients: a prospective study. <b>1988</b> , 72, 267-73	13
116	Expression of class II MHC antigens on alveolar epithelium in fibrosing alveolitis. <b>1987</b> , 67, 182-90	18
115	Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. <b>1984</b> , 58, 68-76	22
114	Expression of MHC class II antigens on bile duct epithelium in experimental graft versus host disease. <b>1985</b> , 60, 449-56	15
113	Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. <b>1985</b> , 118, 151-61	133
112	Pathology of the thymus after allogeneic bone marrow transplantation in man. A histologic immunohistochemical study of 36 patients. <b>1987</b> , 129, 242-56	56
111	Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man. <b>1984</b> , 115, 296-306	32
110	Autoimmune diseases: immunopathology and etiopathogenesis. <b>1982</b> , 108, 319-65	29
109	Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes. <b>1982</b> , 108, 196-205	13
108	Transfusion-associated graft-versus-host disease. <b>1990</b> , 63, 445-54	8
107	Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. <b>2011</b> , 17, 2533-43	57
106	The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks. <b>2014</b> , 8, 1-8	2
105	The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing Risks. <b>2014</b> , 8, 1-11	3
104	Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation. <b>2015</b> , 9, 112-21	5
103	The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation. <b>2017</b> , 11, 24-29	2

102	[Effect of chronic graft versus host disease on relapse and survival in patients with acute myeloid leukemia]. <b>2015</b> , 36, 116-20	
101	[Improved outcome by optimized conditioning regimens with an increased dose of cyclophosphamide in allogeneic peripheral blood stem cell transplantation for severe aplastic anemia]. <b>2017</b> , 38, 662-666	0
100	[Comparison of immune reconstitution at early stage after unmanipulated haploidentical stem cell transplantation between high- and standard- risk Philadelphia chromosome- negative acute lymphoblastic leukemia patients in CR1]. <b>2016</b> , 37, 650-5	
99	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <b>2021</b> ,	0
98	Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <b>2021</b> ,	1
97	Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. <b>2021</b> ,	1
96	Histopathology of intestinal villi in neonatal and paediatric age: main features with clinical correlation - Part I. <b>2021</b> ,	2
95	Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <b>2021</b> ,	1
94	Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics. <b>2021</b> ,	0
93	Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature.. <b>2022</b> ,	1
92	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.. <b>2022</b> , 22, 11	1
91	Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation.. <b>2022</b> ,	
90	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.. <b>2022</b> ,	0
89	HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients.. <b>2022</b> , e14233	
88	Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis.. <b>2022</b> ,	3
87	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.. <b>2022</b> ,	0
86	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.. <b>2022</b> ,	0
85	Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.. <b>2022</b> , 13, 837335	0

- 84 HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. **2022**, 3, 51-67
- 83 A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients.. **2022**, 31, 9636897221076050
- 82 Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. **2022**, 1-9 2
- 81 Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission.. **2022**, 1
- 80 Role of therapeutic drug monitoring of intravenous Busulfan for prevention of sinusoidal obstructive syndrome in children.. **2022**, e14266
- 79 Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.. **2022**, 0
- 78 Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.. **2022**, 1
- 77 The clinical significance of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation.. **2022**,
- 76 Hepatitis B virus vaccination after allogeneic hematopoietic cell transplantation prevents post-transplant HBV reactivation.. **2022**, 0
- 75 Non-neoplastic diseases of the small and large intestines. 1925-1982
- 74 Data\_Sheet\_1.docx. **2020**,
- 73 Data\_Sheet\_2.pdf. **2020**,
- 72 Data\_Sheet\_3.pdf. **2020**,
- 71 Data\_Sheet\_4.pdf. **2020**,
- 70 datasheet1.xls. **2020**,
- 69 image1.tif. **2020**,
- 68 image2.tiff. **2020**,
- 67 table1.docx. **2020**,



- 66 table2.docx. **2020**,
- 65 table3.docx. **2020**,
- 64 table4.docx. **2020**,
- 63 table5.docx. **2020**,
- 62 Progress in bone marrow transplantation in man. **1982**, 1, 40-66 6
- 61 Graft Versus Host Disease. **2022**, 7557-7579
- 60 Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.. **2022**, 0
- 59 Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.. **2022**,
- 58 Ideal body weight is useful for predicting neutrophil engraftment and platelet recovery for overweight and obese recipients in single-unit cord blood transplantation.. **2022**, 0
- 57 Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation.. **2022**, 1
- 56 STR typing of skin swabs from individuals after an allogeneic hematopoietic stem cell transplantation.
- 55 Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors. 13, 0
- 54 Is graft-versus-host disease a reliable model for scleroderma?. **1986**, 16, 509-513 6
- 53 Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. 1
- 52 Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
- 51 Higher risk for chronic graft-versus-host disease ( GvHD ) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation ̄a retrospective study. 0
- 50 Extracorporeal photopheresis for the treatment of chronic graft versus host disease. **2022**, 27, 785-794
- 49 Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. **2022**, 6, 4098-4106 1

- 48 Graft-versus-Host Disease of the Intestine and Liver. **1988**, 8, 543-557 2
- 47 The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. o
- 46 Short- and long-term outcome of allogeneic stem cell transplantation in infants: A single-center experience over 20 years. 10,
- 45 Ocular Chronic Graft-Versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes After Allogeneic Haematopoietic Cell Transplantation. **2022**, o
- 44 Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3ITD-mutated acute myeloid leukemia. o
- 43 Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission. 1-11 o
- 42 Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. o
- 41 Multicenter prospective validation study for international chronic ocular graft-versus-host disease consensus diagnostic criteria. **2022**, 26, 200-208 o
- 40 Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia. **2022**, o
- 39 Impact of Cytogenetic Risk on Outcomes of Non-T-Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. **2022**, o
- 38 Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. o
- 37 Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study included in the ALWP of the EBMT. o
- 36 Nutritional status and prognosis in children with immunodeficiencies undergoing hematopoietic stem cell transplantation. **2022**, o
- 35 Chronic gvhd dictionary Eurograft cost action initiative consensus report. o
- 34 Hematopoietic stem cell transplantation activities and HRQOL of refugee or asylum seeker children in Türkiye: A multicenter study. o
- 33 Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. o
- 32 Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience. **2022**, 14, 5587 o
- 31 Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia. o

- 30 Bone Marrow Transplantation in Pediatrics. **1983**, 30, 549-593 o
- 29 HTLV-1 infection of donor-derived T cells might promote acute graft-versus-host disease following liver transplantation. **2022**, 13, o
- 28 Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).. o
- 27 Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia.. o
- 26 Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation. 1
- 25 Donor Genetic Predisposition to High Interleukin-10 Production Appears Protective against Acute Graft-Versus-Host Disease. **2022**, 23, 15888 o
- 24 Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients. 13, o
- 23 Peritransplant glucocorticoid haploidentical stem cell transplantation is a promising strategy for AML patients with high leukemic burden: Comparison with transplants using other donor types. **2023**, o
- 22 Competitive repopulation and allo-immunological pressure determine chimerism kinetics after T-cell depleted allogeneic stem cell transplantation and donor lymphocyte infusions. **2022**, o
- 21 Nutritional Considerations During Marrow Transplantation. **1983**, 18, 585-596 8
- 20 T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia. **2023**, o
- 19 Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. o
- 18 Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates. **2023**, o
- 17 Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL. o
- 16 Immunologic Aspects of Marrow Transplantation. **1989**, 9, 187-208 o
- 15 HLA, Blood Transfusion and the Immune System. **1984**, 4, 503-534 o
- 14 Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome. o
- 13 Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without Down syndrome in China: A single-center study. 13, o

- 12 Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). **2023**, 37, 799-806 ○
- 11 Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. ○
- 10 Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. ○
- 9 Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. **2023**, 32, 096368972311581 ○
- 8 Adverse impact of a high CD4 / CD8 ratio in the allograft may be overcome by methotrexate- but not mycophenolate- or post-transplant cyclophosphamide-based graft versus host disease prophylaxis. ○
- 7 Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. ○
- 6 Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia. ○
- 5 Incidence, Etiology, Risk Factors, and Outcomes of Bloodstream Infection after a Second Hematopoietic Stem Cell Transplantation. **2023**, ○
- 4 Transplantation Pathology. **2024**, 947-1038 ○
- 3 Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. ○
- 2 Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. **2023**, 18, e0284476 ○
- 1 Role of measurable residual disease quantified by 4 to 6 color flow cytometry before allogeneic hematopoietic stem cell transplantation for high-risk Philadelphia-negative acute lymphoblastic leukemia. **2023**, 7, 016-023 ○